US20130236505A1 - Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment - Google Patents
Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment Download PDFInfo
- Publication number
- US20130236505A1 US20130236505A1 US13/790,101 US201313790101A US2013236505A1 US 20130236505 A1 US20130236505 A1 US 20130236505A1 US 201313790101 A US201313790101 A US 201313790101A US 2013236505 A1 US2013236505 A1 US 2013236505A1
- Authority
- US
- United States
- Prior art keywords
- acid
- spray
- coating
- coating composition
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 230000007935 neutral effect Effects 0.000 title description 10
- 239000011253 protective coating Substances 0.000 title description 4
- 239000008199 coating composition Substances 0.000 claims abstract description 50
- 229920001577 copolymer Polymers 0.000 claims abstract description 47
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 claims abstract description 19
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000008016 pharmaceutical coating Substances 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 110
- 239000006185 dispersion Substances 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 74
- 238000000576 coating method Methods 0.000 claims description 48
- 239000004480 active ingredient Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 34
- 239000002552 dosage form Substances 0.000 claims description 24
- 239000011248 coating agent Substances 0.000 claims description 22
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 19
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 18
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 16
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 14
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 11
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 11
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 10
- 239000001530 fumaric acid Substances 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 8
- 239000001361 adipic acid Substances 0.000 claims description 8
- 235000011037 adipic acid Nutrition 0.000 claims description 8
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 8
- 235000011090 malic acid Nutrition 0.000 claims description 8
- 230000002028 premature Effects 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 90
- 239000007921 spray Substances 0.000 description 83
- 239000002245 particle Substances 0.000 description 81
- 239000003826 tablet Substances 0.000 description 65
- 239000007787 solid Substances 0.000 description 64
- 238000003756 stirring Methods 0.000 description 55
- 238000005507 spraying Methods 0.000 description 51
- 239000000725 suspension Substances 0.000 description 44
- 238000006386 neutralization reaction Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 31
- 239000003963 antioxidant agent Substances 0.000 description 30
- 235000006708 antioxidants Nutrition 0.000 description 30
- 239000000872 buffer Substances 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 28
- 238000000889 atomisation Methods 0.000 description 25
- -1 diethylaminoethyl groups Chemical group 0.000 description 25
- 238000001035 drying Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 238000001694 spray drying Methods 0.000 description 20
- 238000009826 distribution Methods 0.000 description 19
- 238000005259 measurement Methods 0.000 description 19
- 238000000149 argon plasma sintering Methods 0.000 description 18
- 239000007789 gas Substances 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 239000004815 dispersion polymer Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000008187 granular material Substances 0.000 description 14
- 239000000454 talc Substances 0.000 description 14
- 229910052623 talc Inorganic materials 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000873 masking effect Effects 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000006104 solid solution Substances 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000009477 glass transition Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical group 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- 229920003084 Avicel® PH-102 Polymers 0.000 description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 239000000084 colloidal system Substances 0.000 description 5
- 229920000578 graft copolymer Polymers 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 5
- 239000001384 succinic acid Substances 0.000 description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 4
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229960003712 propranolol Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical class CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- LBSFSRMTJJPTCW-DSXUQNDKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LBSFSRMTJJPTCW-DSXUQNDKSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 3
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003356 anti-rheumatic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical class C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 2
- BCCREUFCSIMJFS-UHFFFAOYSA-N 2-hydroxy-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide Chemical compound OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 BCCREUFCSIMJFS-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 229920003083 Kollidon® VA64 Polymers 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical class C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000003098 androgen Chemical class 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940097217 cardiac glycoside Drugs 0.000 description 2
- 239000002368 cardiac glycoside Substances 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960002947 dapiprazole Drugs 0.000 description 2
- RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical class CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000012243 magnesium silicates Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 229960001144 mizolastine Drugs 0.000 description 2
- 229960001165 modafinil Drugs 0.000 description 2
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical class CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960003320 roxatidine Drugs 0.000 description 2
- 229960005224 roxithromycin Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 2
- 229960000652 sertindole Drugs 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 2
- 229960004954 sparfloxacin Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229930002534 steroid glycoside Natural products 0.000 description 2
- 150000008143 steroidal glycosides Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 2
- 229960001661 ursodiol Drugs 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- KVHHQGIIZCJATJ-UHFFFAOYSA-N 1-(4-chlorophenyl)-4-(dimethylamino)-2,3-dimethyl-2-butanol Chemical compound CN(C)CC(C)C(C)(O)CC1=CC=C(Cl)C=C1 KVHHQGIIZCJATJ-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- FSKFPVLPFLJRQB-UHFFFAOYSA-N 2-methyl-1-(4-methylphenyl)-3-(1-piperidinyl)-1-propanone Chemical compound C=1C=C(C)C=CC=1C(=O)C(C)CN1CCCCC1 FSKFPVLPFLJRQB-UHFFFAOYSA-N 0.000 description 1
- BVCOHOSEBKQIQD-UHFFFAOYSA-N 2-tert-butyl-6-methoxyphenol Chemical compound COC1=CC=CC(C(C)(C)C)=C1O BVCOHOSEBKQIQD-UHFFFAOYSA-N 0.000 description 1
- BKZXZGWHTRCFPX-UHFFFAOYSA-N 2-tert-butyl-6-methylphenol Chemical compound CC1=CC=CC(C(C)(C)C)=C1O BKZXZGWHTRCFPX-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 description 1
- KYHQZNGJUGFTGR-LURJTMIESA-N 7-[(2s)-2-hydroxypropyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C[C@@H](O)C KYHQZNGJUGFTGR-LURJTMIESA-N 0.000 description 1
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Chemical class 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical class ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Chemical class 0.000 description 1
- 108010036949 Cyclosporine Chemical class 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 239000004908 Emulsion polymer Substances 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 101150030514 GPC1 gene Proteins 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical class SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical class C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical class OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 241001163248 Schoenocaulon officinale Species 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical class [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002959 anti-hypotensive effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 150000007656 barbituric acids Chemical class 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920003118 cationic copolymer Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002735 clobutinol Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000011557 critical solution Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical class O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Chemical class 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical class C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical class SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- DKRSEIPLAZTSFD-UHFFFAOYSA-N d-quinotoxine Natural products C12=CC(OC)=CC=C2N=CC=C1C(=O)CCC1CCNCC1C=C DKRSEIPLAZTSFD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical class C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical class C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical class C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 1
- 229960002877 dihydralazine Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical class C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229960001275 dimeticone Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical class C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- 229960005387 etofylline Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical class C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- USSIQXCVUWKGNF-QGZVFWFLSA-N levomethadone Chemical compound C=1C=CC=CC=1C(C[C@@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-QGZVFWFLSA-N 0.000 description 1
- 229960002710 levomethadone Drugs 0.000 description 1
- 229940087121 levomethadyl Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960003134 mepindolol Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 description 1
- 229960005103 metixene Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 150000003810 morphinanes Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 229960003226 nikethamide Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960004918 nimorazole Drugs 0.000 description 1
- MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960004031 omoconazole Drugs 0.000 description 1
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 229940124585 oral penicillin Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 229960005113 oxaceprol Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960002371 pentifylline Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000000590 phytopharmaceutical Substances 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004310 piribedil Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 229960003510 propiverine Drugs 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 229960000918 protionamide Drugs 0.000 description 1
- 229960004767 proxyphylline Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 1
- 229960001007 quinaprilat Drugs 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- 229960001811 quinine hydrochloride Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 229960000341 spaglumic acid Drugs 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940120904 succinylcholine chloride Drugs 0.000 description 1
- FFSBEIRFVXGRPR-UHFFFAOYSA-L succinylcholine chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C FFSBEIRFVXGRPR-UHFFFAOYSA-L 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 1
- 229960001326 sultamicillin Drugs 0.000 description 1
- 229960002573 sultiame Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 1
- 229960004267 taurolidine Drugs 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229960002876 tegaserod Drugs 0.000 description 1
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- 229960003352 tertatolol Drugs 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229960005344 tiapride Drugs 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 1
- 229960003070 tioxolone Drugs 0.000 description 1
- 229960001899 tiropramide Drugs 0.000 description 1
- FDBWMYOFXWMGEY-UHFFFAOYSA-N tiropramide Chemical compound C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CC1=CC=C(OCCN(CC)CC)C=C1 FDBWMYOFXWMGEY-UHFFFAOYSA-N 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960005334 tolperisone Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 1
- 229960002341 trifluperidol Drugs 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 229960000832 tromantadine Drugs 0.000 description 1
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 description 1
- 229960003819 vecuronium Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- DKRSEIPLAZTSFD-LSDHHAIUSA-N viquidil Chemical compound C12=CC(OC)=CC=C2N=CC=C1C(=O)CC[C@@H]1CCNC[C@@H]1C=C DKRSEIPLAZTSFD-LSDHHAIUSA-N 0.000 description 1
- 229960003353 viquidil Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229960004855 xantinol nicotinate Drugs 0.000 description 1
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
- 229960000537 xipamide Drugs 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention relates to pharmaceutical protective coatings with good resistance in a neutral environment, where, for the purpose of odor masking or for protecting against moisture, pharmaceutical dosage forms are provided with a film coating based on a cationic copolymer present in partially neutralized form which is obtained by means of free-radical emulsion polymerization of a monomer mixture comprising N,N-diethylaminoethyl methacrylate.
- the present invention also relates to the production of corresponding coatings and use of corresponding coating compositions for producing protective coatings with good resistance in a neutral environment.
- Excessively thick coatings are not only esthetically unsatisfactory, because they are more rough than beautifully smooth, but also economically unsatisfactory because more coating composition is required to produce greater layer thicknesses and, moreover, the processing times are longer. Added to this is the fact that excessively thick coatings cause an undesired slower release of the active ingredient in the acidic environment of the stomach, where they are supposed to release the active ingredient as quickly as possible.
- the aim when developing coating compositions will therefore always be to produce the thinnest possible film coatings, although these have to satisfy the functional demands, as in the present case of taste masking. Desirable application amounts are therefore usually in the range from 1 to 20 mg/cm 2 .
- the coatings also have to be stable for an adequate time in respect of the taste masking.
- Oral Dispersible Tablets in which active ingredient crystals or active ingredient micropellets provided with a taste-masked coating are embedded into a matrix which disintegrates rapidly in the oral environment, it often arises that the coated active ingredient crystals or micropellets get caught up in interdental spaces for a while. If the coating then has inadequate denseness to disintegration in the neutral environment of the oral cavity, then unpleasant taste sensations can occur as a result.
- the requirement placed on suitable coatings is therefore adequate resistance to release of the active ingredient at neutral pH values of at least one hour, preferably even of two hours.
- a further requirement is the good redispersibility in water of the film-forming polymers which form the basis of the coating compositions used.
- the film-forming polymers used for the taste masking are usually pH-dependent soluble polymers which are water-insoluble in a neutral environment, but in most cases dissolve rapidly in the acidic environment of the stomach in order to facilitate a rapid release of the active ingredient.
- DE-B 2512238 teaches the use of a powder obtained by spray-drying a polymer dispersion for producing coating solutions for these drug forms.
- dispersions used for the spray-drying reference is made to DE 1090381, DE 1219175 and DE 2135073.
- DE 3049179 A1 is an application of addition to DE 2512238 and relates to the use of a powder obtained by spray-drying according to the teaching of the last-mentioned document in the form of an aqueous suspension which additionally comprises a plasticizer for producing coatings by thermogelation.
- WO 00/05307 deals with the provision of coatings and binders for drug forms which comprise (meth)acrylate copolymers which have monomer radicals with tertiary amino groups, the intention being for simple dry or aqueous further processing to be possible.
- WO 02/067906 relates to coating and binding compositions having improved water-vapor permeability compared with those described in WO 00/05307.
- the coating and binding compositions are produced using a mixture which comprises (a) a copolymer of C 1 -C 4 -esters of (meth)acrylic acid and further (meth)acrylate monomers with functional tertiary ammonium groups in powder form having an average particle size from 1 to 40 ⁇ m, (b) an emulsifier with an HLB value of at least 14 and (c) a C 12 -C 18 -monocarboxylic acid or a C 12 -C 18 -hydroxyl compound.
- WO 2004/019918 describes coating and binding compositions which correspond to those described in WO 00/05307 and WO 02/067906 as regards their composition.
- EP88951 A2 describes a process for coating drugs using a water-dispersed coating composition based on emulsion polymers, where the coating compositions may be partially present in salt form.
- the coating compositions can also be obtained from redispersed powders.
- WO 97/42255 describes the spray-drying of polymer powders that can be redispersed in aqueous solution and comprise free acid- or base-carrying copolymers, where, before the spray drying, the pH values of the dispersions have to be adjusted with the help of a buffer system.
- EP 262326 A2 describes a process for producing a redispersible plastics powder.
- WO 2009/016258 discloses the production of the aqueous polymer dispersions of cationic polymers based on N,N-diethylaminoethyl methacrylate as are used according to the invention and the use thereof for the coating of drugs. Although it is described that the cationic polymers can be partially neutralized a series of inorganic and organic acids is listed quite generally as being suitable for the partial neutralization.
- Embodiments of the present invention to provide coating compositions which impart good resistance to premature active ingredient release to a pharmaceutical dosage form, and at the same time also have a good redispersibility in water.
- the coating compositions are applied in application amounts of 1 to 20 mg/cm 2 , and in the case of an application amount of 4 mg/cm 2 , the coatings have a resistance to release of the active ingredient in the aqueous environment at pH 6.8 of at least 80% after 30 min.
- coating compositions for coatings of dosage forms comprising at least one pharmaceutical active ingredient with a resistance to premature release of the active ingredient
- the coating compositions comprise, as film-forming polymers, copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in the weight ratio of the monomers of 35:65 to 55:45, wherein the copolymers in the coating composition are partially neutralized with C 3 -C 10 -dicarboxylic acids.
- the coating compositions are obtained in powder form and redispersed in water prior to application to the dosage form.
- film-forming coating compositions for pharmaceutical dosage forms based on copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in the weight ratio of the monomers of 35:65 to 55:45, where the copolymers are present partially neutralized with C 3 -C 10 -dicarboxylic acids, for protecting active ingredient-containing pharmaceutical dosage forms against premature active ingredient release in an aqueous environment at pH 6.8 has been found.
- the resistance to premature release of the pharmaceutical active ingredient in an aqueous environment at pH values in the region of 6.8 is determined with the help of the so-called “paddle model”.
- This measurement method is described in the USP.
- the coated dosage forms are tested in phosphate buffer at pH 6.8+/ ⁇ 0.05 with the help of a so-called “paddle apparatus” (apparatus 2) according to USP.
- the phosphate buffer is prepared by dissolving 34.025 g of potassium dihydrogen phosphate in water in a calibrated 5 l measuring flask, adding 112 ml of 1 molar NaOH and topping up to the calibration mark of the 5 l measuring flask.
- Coatings according to the invention satisfy the criterion that, for an application amount of 4 mg/cm 2 , they have a resistance to release of the active ingredient in an aqueous environment at pH 6.8 of at least 80% after 30 min.
- Measurement takes place under atmospheric pressure at 25° C.
- the release of the active ingredient takes place by photometric determination. The release is determined at intervals of 30 min.
- a resistance of 80% after 30 min means that, after 30 min, not more than 20% of the active ingredient has been released.
- the resistance after 30 min is 100%, which means that, within this period, no detectable amounts (less than 2%) of active ingredient are released from the dosage forms.
- the resistance at pH 6.8 should be at least 60%.
- Dicarboxylic acids suitable according to the invention have a chain length of from 3 to 10 carbon atoms.
- Suitable dicarboxylic acids are, in particular, unbranched dicarboxylic acids which have terminal acid groups.
- Suitable dicarboxylic acids are also those which are substituted with one or two hydroxy groups.
- dicarboxylic acids which have a first pK a value of greater than 2 and a second pK a value of greater than 4.
- dicarboxylic acids which have a first pK a value of greater than 2.5 and a second pK a value of greater than 5.
- the pK a value is the negative base ten logarithm of the acid constant, where the acid constant at 25° C. and atmospheric pressure is intended.
- Suitable dicarboxylic acids which carry no further substituents besides the acid groups are the saturated alkanedicarboxylic acids malonic acid, succinic acid, glutaric acid, adipic acid or sebacic acid.
- Suitable alkanedicarboxylic acids substituted with one or two hydroxy groups are malic acid (2-hydroxysuccinic acid) or tartaric acid (2,3-dihydroxysuccinic acid).
- a suitable unsaturated dicarboxylic acid is primarily fumaric acid.
- dicarboxylic acids which produce a particularly good resistance of the coatings
- those acids which produce a particularly good redispersibility of the powders are e.g. adipic acid with sulfuric acid or succinic acid with oxalic acid.
- Partial neutralization within the context of the invention means that 2 to 15, preferably 4 to 10 mol % of the diethylaminoethyl groups are present in salt form.
- the copolymers present in the dispersions preferably have a K value (determined in accordance with Fikentscher on a 1% strength solution in N-methylpyrrolidone (NMP)) in the range from 40 to 60.
- the glass transition temperature T G determined by means of DSC “Differential Scanning calorimetry” is preferably in a range from 40 to 70° C., particularly preferably 52 to 62° C.
- the samples are firstly heated to 150° C. and then rapidly cooled from 150° C.
- the measurement of the glass transition temperature takes place at a heating rate of 20° K/min.
- the minimum film-forming temperature is determined in accordance with the method described in DIN ISO 2115 and is in the range from 40 to 70° C., preferably 50 to 65° C.
- the measurement accuracy of the method is in the region of plus/minus 5° C.
- copolymers present in the dispersions are essentially random copolymers.
- the average particle diameter of the polymer particles present in the polymer dispersion is preferably in a range from 70 to 200 nm, particularly preferably from 80 to 150 nm, in particular from 90 to 130 nm.
- the particle size distribution is preferably essentially unimodal.
- the LT value of the aqueous dispersions used according to the invention is preferably at least 70%, particularly preferably at least 80%.
- the determination of the light transmission is described e.g. in Dieter Distler, Wässrige Polymerdispersionen [Aqueous polymer dispersions], Wiley-VCH (1999), p. 40.
- a copolymer which has a weight ratio of methyl methacrylate (MMA) to diethylaminoethyl methacrylate (DEAEMA) of 55:45.
- MMA methyl methacrylate
- DEAEMA diethylaminoethyl methacrylate
- Such a copolymer is also commercially available as Kollicoat® Smartseal, BASF SE.
- the C3-C10-dicarboxylic acids specified at the start are added to the copolymer power or to the corresponding aqueous dispersion.
- amounts of acid are added such that the basic groups are present partially in the form of the acid salts.
- 1 to 20 mol % of the basic groups can be present in salt form, preferably 2 to 15 mol %, particularly preferably 5 to 10 mol % of the basic groups are neutralized.
- the partial neutralization of the copolymer of MMA/DEAMA can take place either in the aqueous primary dispersion, or else on the powder or during or after aqueous redispersion of a powder.
- the copolymer in powder form can be obtained by spraying processes or by freeze-drying.
- the dicarboxylic acids can be added to the aqueous polymer dispersion prior to a spray-drying. If the acid is incorporated prior to the spray drying, then this can be stirred into the aqueous dispersion using customary methods.
- a partially neutralized aqueous primary dispersion can be converted to the powder form by freeze-drying.
- the acid can also be added before or during the redispersion of a powder produced beforehand from the primary dispersion.
- the incorporation of the acid into the polymer powder can take place such that firstly the polymer powder is coarsely predispersed by means of a simple stirrer, then the acid is added and complete redispersion is achieved by means of further stirring. The redispersion is usually very rapid and, after just 10 min, finely divided dispersates are present.
- the polymer powder and the acid are firstly mixed and this powder mixture is introduced into water.
- a completely neutralized polymer powder can also firstly be prepared, which is then adjusted to the desired degree of partial neutralization by mixing with an unneutralized polymer powder.
- the amounts by weight of acids to be used in individual cases is governed by the particular molecular weight of the C3-C10-dicarboxylic acid and the desired degree of neutralization.
- the treatment with acids is carried out such that the pH of the aqueous dispersion, of the powder or of the powder redispersed in water is in the range from 5 to 9.
- the addition of the acid or of the acidic salt is added such that the pH of the aqueous dispersion, of the powder or of the water-redispersed powder is in the range from 6 to 8.
- embodiments of the invention relate to the partial neutralization of the copolymers of MMA/DEAMA in powder form.
- Preferred procedures for producing the powder form of the copolymers are spraying processes.
- the solids content of the dispersions used according to the invention for the spraying processes is preferably 10 to 50% by weight, particularly preferably 20 to 40% by weight.
- the dispersions used according to the invention preferably have solids contents which are within these ranges before and after the ultrafiltration. It is of course likewise possible to subject a diluted polymer dispersion to a concentration by ultrafiltration prior to the spraying process.
- the coating compositions used for producing the coatings according to the invention are obtained by redispersion in water, the powder obtained by a spraying process being redispersed using low-shear stirring apparatuses at revolutions up to 1000 rpm.
- low-shear stirring apparatuses at revolutions up to 1000 rpm.
- high-shear dispersing apparatuses at revolutions of >5000 rpm. This can take place according to the invention without the fine particles formed during the redispersion agglomerating and the preparation coagulating.
- the average particle size of the polymer powder redispersed in water is at most 5 times, preferably at most 3 times, particularly preferably at most 2 times, that of the underlying primary dispersion.
- Average particle sizes refer here to the Z-Average value, which is determined by light scattering by means of a “Malvern Zetasizer nano S” as Z-Average value.
- Coating compositions can be prepared e.g. by intimately mixing a by redispersing the polymer powder obtained according to the invention to give an aqueous polymer dispersion, to which preferably at least one further auxiliary is added.
- Suitable spraying processes are in principle spray-drying, agglomerating spray-drying, spray granulation (spray fluidized-bed drying) or spray agglomeration.
- the conditions specified below for carrying out the atomization and drying refer to all embodiments of the spraying process which can be carried out in principle, whether normal spray drying, spray granulation or agglomerating spray drying.
- the atomization preferably takes place as hydrodynamic atomization as a result of liquid pressure or air pressure via nozzles such as, for example, single-material or multiple-material nozzles or via atomizing disks.
- Suitable spraying devices are conventional spray towers into which the polymer dispersion to be atomized is introduced from above.
- the polymer powders obtained can be discharged at the lower end and be separated off from the drying-gas stream in a downstream cyclone.
- Drying gases which can be used are air or inert gases such as nitrogen, argon or helium.
- the drying gases can be introduced countercurrently or cocurrently to the liquid droplets produced by the atomization through the spraying apparatus.
- the drying gas is preferably used cocurrently.
- the entry temperature of the drying gas is kept at least 20° C., preferably at least 40° C., above the glass transition temperature and, according to one embodiment, also at least 20° C., preferably at least 40° C., above the dynamic freezing temperature and at least 20° C., preferably at least 40° C., above the minimum film-forming temperature of the polymer.
- the entry temperature of the drying gas into the spraying apparatus is particularly preferably kept at 100 to 140° C.
- the exit temperature of the drying gas from the spraying apparatus is kept at 45 to 70° C.
- the entry temperature of the drying gas into the spraying apparatus is kept at 110 to 130° C. and the exit temperature of the drying gas from the spraying device is kept at 50 to 60° C.
- the exit temperature of the drying gas is very particularly preferably in the same temperature range plus/minus 5° C. as the minimum film-forming temperature.
- the evaporation of the water in the spraying apparatus can take place either at atmospheric pressure or at 0.06 to 0.12 MPa.
- polymeric spraying auxiliaries such as polyvinyl alcohols, mixtures of polyvinyl alcohol and a graft polymer of polyethylene glycol as graft base and polyvinyl alcohol side chains (commercially available as Kollicoat® Protect), polyvinylpyrrolidones, alkylated and/or hydroxyalkylated celluloses, starch derivatives, lignosulfonates, polyacrylic acids or polyacrylamides can also be added to the aqueous polymer dispersions. Suitable amounts of such spraying auxiliaries are in the range from 0.1 to 30, preferably 1 to 10% by weight, based on the solids content.
- antiblocking agents can also be added to the aqueous polymer dispersions.
- Suitable antiblocking agents are e.g. aluminum silicates such as bentonite, also kieselguhr, colloidal silica, precipitated silica, diatomaceous earth, calcium carbonate, titanium dioxide, zinc oxide, magnesium silicates such as talc or tricalcium phosphate.
- Suitable amounts of such antiblocking agents are in the range from 0.1 to 15, preferably 0.5 to 5% by weight, based on the solids content.
- auxiliaries can also be added to the aqueous polymer dispersions.
- Suitable auxiliaries may be: aroma substances, taste-improving substances, sweetening agents (sugars, sugar alcohols, sweeteners such as e.g. aspartame, saccharine-Na, sodium cyclamate), glidants, wetting agents, release agents, antisticking agents, stabilizers, antioxidants, pore formers, neutralizers, luster agents, dyes, pigments, disinfectants or preservatives, thickeners or plasticizers.
- sweetening agents sucgars, sugar alcohols, sweeteners such as e.g. aspartame, saccharine-Na, sodium cyclamate
- glidants wetting agents
- release agents antisticking agents
- stabilizers antioxidants
- pore formers neutralizers
- luster agents dyes, pigments, disinfectants or preservatives, thickeners or plasticizers.
- the conversion to powder can take place by means of a spray granulation.
- the aqueous polymer dispersion to be dried is likewise atomized and the droplets produced then come into contact in a fluidized bed with seed particles that have been introduced as initial charge.
- the seed particles grow to give larger granule particles, with the formation of an onion-peel-like structure around the particle used as seed material.
- Conversion to the powder form can also take place with the help of agglomerating spray drying.
- the polymer dispersion is atomized in a spray tower as described above, where fine dust which is removed from the drying zone is at the same time blown into the atomizing zone, in which the aqueous polymer dispersion is present in the form of fine droplets.
- the fine dust particles stick together here to give relatively large aggregates with a blackberry-like structure.
- a fluidized bed can also be connected, in which the water content of the particles formed can be further reduced.
- the resulting aggregates can have particle sizes of from 150 to 1000 ⁇ m, preferably from 200 to 500 ⁇ m.
- the entry temperature is selected at least 20° C. and preferably at least 40° C.
- the exit temperature of the drying gas from the spraying apparatus is 40 to 85° C., preferably 45 to 70° C.
- the entry temperature of the drying gas into the spraying apparatus is kept at 100 to 140° C. and the exit temperature of the drying gas from the spraying apparatus is kept at 45 to 70° C.
- the entry temperature of the drying gas into the spraying apparatus is kept at 110 to 130° C. and the exit temperature of the drying gas from the spraying apparatus is kept at 50 to 60° C.
- spraying auxiliaries such as e.g. aluminum silicates such as bentonite, kieselguhr, colloidal silica, precipitated silica, diatomaceous earth, calcium carbonate, titanium dioxide, zinc oxide, magnesium silicates such as talc or tricalcium phosphate can be blown into the spray tower during the spraying process in amounts of from 0.1 to 15, preferably 0.5 to 5% by weight, based on the polymer powder.
- the particle sizes of the powder formed by spraying processes are governed by the particular variant.
- particle sizes of from 10 to 150 ⁇ m can be achieved.
- a spray granulation such as, for example, a spray fluidized-bed drying
- larger particle sizes of from 150 up to 1000 ⁇ m can be achieved.
- particle sizes of from 150 to 1000 ⁇ m can be achieved.
- the copolymers are obtained as free-flowing powders which, for the purposes of the present invention, means that the powders, upon determining the flowability in accordance with DIN ISO 4324 using Pfrengle equipment without stirring aid, flow out of the funnel freely and completely.
- the residual solvent content is usually not more than 5% by weight, based on the solids content of the powder.
- the redispersible copolymer powders to be used according to the invention for producing the coatings have, in water at a solids content of 20% by weight, low viscosities of preferably less than 300 mPas, particularly preferably less than 200 mPas and in particular less than 100 mPas (values determined by means of Brookfield viscometer at 20° C. and 100 s ⁇ 1 ). Such viscosities are of particular importance for many applications.
- the polymer dispersions can be treated, as mentioned, with sparingly water-soluble antioxidants prior to being converted to the powder form.
- antioxidants is known per se to the person skilled in the art (see e.g. Römpp-Lexikon der Chemie [Lexicon of Chemistry], 9th edition, 1989, Georg-Thieme-Verlag, Stuttgart) and refers to substances which are intended to inhibit or prevent undesired changes brought about by oxygen or other oxidative processes.
- suitable antioxidants for stabilizing the coating compositions are sparingly water-soluble antioxidants, i.e. antioxidants whose solubility in water at 20° C. is not more than 1 g/l.
- suitable antioxidants are primarily the lipophilic substances tocopherol, tocopherol acetate, ascorbyl palmitate, ascorbyl stearate, t-butylhydroquinone, t-butylhydroxyanisole, t-butylhydroxytoluene, octyl gallate or dodecyl gallate or combinations thereof.
- the antioxidants used can also be dissolved in an organic solvent.
- Suitable organic solvents are those solvents which, on the one hand, are miscible with water to a sufficient extent that a concentration of at least 10% by weight in water can be achieved, but, on the other hand, are able to dissolve the sparingly water-soluble antioxidants.
- Suitable solvents are alcohols such as e.g. ethanol or isopropanol, ketones such as e.g. acetone, methyl ethyl ketone and esters such as e.g. methyl acetate. Usually, these solvents have boiling points below 100° C.
- the antioxidants can be brought into organic solution in a manner customary per se.
- concentration is selected such that 10 to 1000 g of antioxidant are used per liter of solvent.
- amount of organic solvent is selected such that 1 to 20% by weight of solvent are used, based on the weight of the aqueous dispersion.
- the antioxidants can be incorporated into the aqueous dispersion in the form of an aqueous micellar solution.
- the substances are brought into solution in the presence of solubilizing substances (“solubilizers”) (as regards the term “solubilization”, see Römpp-Chemielexikon, [Chemistry Lexicon], 9th edition).
- solubilizers are surfactants such as e.g. sodium docusate or sodium dodecylsulfate, ethoxylated fats, ethoxylated fatty acids, ethoxylated fatty alcohols or polymeric solubilizers.
- Suitable polymeric solubilizers are primarily amphiphilic copolymers.
- amphiphiilic copolymers are understood as meaning copolymers which are composed of hydrophilic and hydrophobic segments.
- the segments can also have a LCST (Lower Critical Solution Temperature).
- the segments are for their part polymer chains which, on account of their composition and/or the monomers used for producing the segments, are either hydrophilic or hydrophobic.
- the amphiphilic copolymers can be block polymers or graft polymers. Besides linear block polymers, the structure of the copolymer can also be comb-like or star-like.
- hydrophobic side chains and a hydrophilic graft base may be present, or hydrophilic side chains and a hydrophobic graft base.
- the side chains may either be grafted to or grafted on.
- Suitable amphiphilic copolymers are disclosed for example in WO 2007/017452, WO 2007/051743, WO 2007/065845 and WO 2007/065846, to the description of which with regard to suitable amphiphilic copolymers and their production reference is hereby made. Further amphiphilic copolymers are for example poloxamers.
- Suitable hydrophilic segments are N-vinyllactam homopolymer or copolymer chains, in particular N-vinylpyrrolidone-containing polymers, as well as polyvinyl alcohol chains or polyethers.
- Suitable hydrophobic segments are, for example, homopolymers or copolymers of N-vinyl acetate.
- a suitable comonomer is for example N-vinylcaprolactam.
- a preferred polymeric solubilizer is a graft polymer commercially available under the name Soluplus®, BASF SE, with PEG 6000 as graft base and a copolymer side chain produced from vinyl acetate and N-vinylcaprolactam.
- the aqueous antioxidant solubilizates comprise 0.5 to 30% by weight, preferably 1 to 20% by weight, of antioxidant and 1 to 50% by weight, preferably 1 to 30% by weight, of solubilizer. Overall, the amount is selected such that 1 to 40% by weight of aqueous antioxidant solubilizate, based on the weight of the aqueous dispersion, are used.
- the sparingly water-soluble antioxidants can be introduced into the aqueous dispersion of the polymeric coating composition in the form of finely divided aqueous dispersions.
- dispersions is the term used to refer to two-phase systems which may be either solid/liquid (suspensions) or liquid/liquid (emulsions).
- the average particle size (d4,3) of the antioxidants here should be less than 20 ⁇ m, preferably less than 10 ⁇ m, particularly preferably less than 3 ⁇ m.
- the antioxidants can be dissolved in emulsifiers and then dispersed in water.
- the antioxidants can also be added directly to water and be dispersed with the aid of emulsifiers using high-shear dispersing tools. Particular preference is given here to heating the preparation to a temperature above the melting point of the antioxidant, as a result of which an emulsion is formed.
- This hot emulsion can be added directly to the polymer dispersion with stirring. Alternatively, it can also be cooled beforehand, as a result of which a finely divided suspension is formed. It is particularly preferred to add the hot emulsion to a polymer dispersion which likewise has a temperature above the melting point of the antioxidant.
- Suitable emulsifiers are in principle all classes of interface-active substances with an HLB value of >10 (re the Hydrophilic-Lipophilic-Balance value, see Fiedler, Encyclopedia of Excipients, Editio Cantor Verlag Sixth edition, 2007, pages 112-119).
- Suitable emulsifiers are in principle all ethoxylated fatty acids, ethoxylated fatty alcohols, ethoxylated fatty acid ethers or ethoxylated fatty acid esters with corresponding HLB values.
- ethoxylated sorbitan, stearyl, oleyl, lauryl or palmityl derivatives for example Solutol® HS (Macrogol 15 hydroxystearate) or ethoxylated hydrogenated castor oil, such as, for example, Cremophor® RH40 (ethoxylated with 40 ethylene oxide units) or the corresponding Eumulgin® grades, for example, are suitable.
- Solutol® HS Microgol 15 hydroxystearate
- ethoxylated hydrogenated castor oil such as, for example, Cremophor® RH40 (ethoxylated with 40 ethylene oxide units) or the corresponding Eumulgin® grades, for example, are suitable.
- emulsifiers are poloxamers (polyethylene oxide-polypropylene oxide block copolymers).
- the aqueous antioxidant/emulsifier dispersions comprise 1 to 50% by weight, preferably 2 to 30% by weight, of antioxidant and 0.1 to 30% by weight, preferably 0.5 to 10% by weight, of emulsifier.
- the amount is selected such that 1 to 40% by weight of aqueous antioxidant/emulsifier dispersion are used, based on the weight of the aqueous polymer dispersion.
- the antioxidants can be used in the form of a so-called “solid solution”.
- solid solution is known to the person skilled in the art and refers to a molecularly disperse distribution of one solid in another solid.
- the antioxidants can be incorporated as solid solutions into a suitable solid solubilizer or into a polymeric protective colloid.
- the resulting solid solution can then be incorporated directly in solid form into the aqueous coating composition dispersion, or be converted beforehand into a micellar aqueous solution or into a colloidal solution and then be incorporated into the aqueous coating composition dispersion.
- the solid solutions can for example be produced by dissolving the antioxidants together with the solubilizer or the protective colloid in a suitable solvent and then evaporating the solvent.
- the solid solution of the antioxidants can be prepared by melt extrusion, where antioxidants and solubilizers or polymeric protective colloids are melted together and then extruded, molded and solidified.
- the granular solid melt extrudates obtained after the extrusion can be incorporated particularly advantageously into the aqueous dispersion of the polymeric coating composition.
- Suitable matrix polymers and protective colloids for solid solutions here are the amphiphilic copolymers already mentioned, in particular Soluplus®, or poloxamers such as Lutrol® F86, but also nonamphiphilic polymers such as e.g.
- polyvinylpyrrolidones vinylpyrrolidone-vinyl acetate copolymers, polyethylene glycols, polyvinyl alcohols, polyvinyl alcohol-polyethylene glycol graft copolymers or hydroxyalkylated celluloses.
- Coating compositions can be produced e.g. by intimately mixing a by redispersing the polymer powder obtained according to the invention to give an aqueous polymer dispersion, to which preferably at least one further auxiliary is added.
- Suitable additional auxiliaries may be: aroma substances, taste-improving substances, sweetening agents (sugars, sugar alcohols, sweeteners such as e.g. aspartame, saccharine-Na, sodium cyclamate), glidants, wetting agents, release agents, antisticking agents, stabilizers, antioxidants, pore formers, neutralizing agents, luster agents, dyes, pigments, disinfectants or preservatives, thickeners, plasticizers etc.
- sweetening agents sucgars, sugar alcohols, sweeteners such as e.g. aspartame, saccharine-Na, sodium cyclamate
- glidants wetting agents
- release agents antisticking agents
- stabilizers antioxidants
- pore formers pore formers
- neutralizing agents luster agents
- the MMA/DEAEMA polymer powder can be ground prior to redispersion in water.
- the grinding can also take place in the presence of the specified additional auxiliaries.
- Customary amounts of the auxiliaries are in a range from in each case 0 to 70% by weight, preferably 0 to 60% by weight, in particular 1 to 50% by weight, based on the total weight of the solid of the coating composition.
- the coatings are produced with a coating composition according to the invention in aqueous form.
- the application of the coating composition can take place in aqueous form by granulation, pouring, spreading or by means of spray application.
- the coating composition obtained according to the invention can also be applied in powder form to the pharmaceutical dosage forms.
- the application is as aqueous polymer dispersion obtained by redispersing a pulverulent coating composition according to the invention.
- any dispersing apparatus is suitable for the redispersion.
- the redispersion takes place preferably with the application of low shear forces, preferably by means of a blade, propeller, anchor stirrer or a comparable stirring tool.
- the polymer powders according to the invention are hereby redispersed spontaneously and rapidly. The redispersion of the polymer powder in water is usually completed in 10 min.
- plasticizers such as e.g. triethyl citrate, tributyl citrate, diethyl sebacate, dibutyl sebacate, acetyl triethyl citrate.
- the production of the finely dispersed dispersions by redispersing powders can also take place at very high shear forces such as for example in a rotor-stator apparatus, which is also called Ultra-Turrax, or a colloid mill.
- the introduction of high shear forces is regulated in a rotor-stator apparatus via the number of revolutions of the apparatus.
- the redispersion takes place with the help of a dispersing apparatus at ⁇ 5000 rpm.
- This process is particularly advantageous if further coarsely particulate additives or agglomerated additives additionally have to be incorporated into the dispersion which necessitate a special comminution. The separate comminution of these additives in water and subsequent addition to the redispersed polymer powder is thus dispensed with.
- the redispersible polymer powders according to the invention are mixed with further customary coating constituents and/or additives described above to produce so-called ready-to-use preparations which comprise all of the required constituents of a finished coating. These are present in powder or granule form. The user only needs to stir them into water to produce a ready-to-spray suspension.
- These ready-to-use preparations are produced by dry mixing, grinding, compaction or granulation of the constituents with a granulating liquid, followed by a drying step.
- a polymer powder partial neutralized according to the invention can be granulated with an aqueous suspension comprising pigments and optionally further auxiliaries. These granules can then be redispersed to give a spray suspension.
- the coating compositions according to the invention can additionally comprise at least one further polymer component.
- mixtures of at least two dispersions, at least one dispersion and at least one solution, at least one dispersion and at least one powder, at least two powders, etc. can be used.
- the application amount of the coating composition is preferably in the range from 1 to 20 mg/cm 2 , preferably 2 to 15 mg/cm 2 , particularly preferably 4 to 12 mg/cm 2 .
- the coating compositions serve to produce coatings for pharmaceutical dosage forms which are intended to be rapidly releasing in the acidic environment of the stomach, i.e. the coatings according to the invention are soluble in gastric juice.
- rapidly releasing means that at least 80% of the active ingredient has been released after 60 min at 25° C. under atmospheric pressure according to the paddle model (medium: 0.1 N HCl).
- Coatings obtained according to the invention should not dissolve in the oral cavity and throat in the neutral or almost neutral environment of saliva.
- the coatings according to the invention can be used for taste masking or for protecting against moisture.
- the water vapour permeability of the coatings is very low, as a result of which active ingredients that are sensitive to moisture are protected.
- compositions which can be provided with the coatings according to the invention are tablets, capsules or pellets. Furthermore, active ingredient crystals can also be provided with the coatings according to the invention.
- the coating compositions obtained by the process according to the invention are suitable for dosage forms of in principle any desired pharmaceutical active ingredients, which can preferably be administered in isolated or protected form, such as antidepressants, beta receptor blockers, antidiabetic agents, analgesics, antiphlogistics, antirheumatics, antihypotensives, antihypertensives, psychoactive drugs, tranquilizers, antiemetics, muscle relaxants, glucocorticoids, agents for treating ulcerative colitis or Crohn's disease, antiallergic agents, antibiotics, antiepileptics, anticoagulants, antimycotics, antitussives, arteriosclerotic agents, diuretics, enzymes, enzyme inhibitors, gout remedies, hormones and inhibitors thereof, cardiac glycosides, immunotherapeutic agents and cytokines, laxatives, antilipanic agents, gastrointestinal therapeutic agents, antimigrane agents, preparation of mineral substances, otologic agents, agents to treat Parkinson's disease, thyroid therapeutic agents, spasmolytic
- Suitable active ingredients are: acarbose, nonsteroidal antirheumatics, cardiac glycosides, acetylsalicylic acid, virustatic agents, aclarubicin, aciclovir, cisplatin, actinomycin, ⁇ - and ⁇ -sympathomimetics, allopurinol, alosetron, alprostadil, prostaglandins, amantadine, ambroxol, amlodipine, methotrexate, 5-aminosalicylic acid, amitriptyline, amlodipine, amoxicillin, anastrozole, atenolol, atorvastatin, azathioprine, balsalazide, beclomethasone, betahistine, bezafibrate, bicalutamide, diazepam and diazepam derivatives, budesonide, bufexamac, buprenorphine, methadone, calcium salts,
- the active ingredients can also be used in the form of their pharmaceutically acceptable salts or derivatives, and in the case of chiral active ingredients, both optically active isomers and also racemates or diastereoisomer mixtures can be used.
- the compositions according to the invention can also comprise two or more pharmaceutical active ingredients.
- the coating compositions can be used for coating extrudates, minitablets, capsules, soft capsules, granules, pellets, micropellets, microcapsules, nanocapsules or crystals.
- the coated granules, pellets, micropellets, microcapsules, crystals can be mixed with suitable auxiliaries and compacted to give tablets, which disintegrate in the aqueous environment of the oral cavity and release the coated fine shaped articles again.
- suitable auxiliaries i.e. the so-called oral dispersibles, i.e. tablets which disintegrate in the mouth within a short time and release the taste-masked small shaped articles.
- coating compositions can also be used advantageously for coating tablets.
- Active ingredient classes and substances which can often bring about an unpleasant bitter taste and can be formulated advantageously according to the invention are e.g.:
- analgesics and antirheumatics such as paracetamol, diclofenac, aceclofenac, ibuprofen, ketoprofen, flurbiprofen, acetylsalicylic acid, levacetylmethadol and oxycodone; psychoactive drugs, such as promethazines, donepezil, modafinil, nefazodone, reboxetine, sertindole and sertraline; antibiotics, such as erythromycin, roxithromycin, clarithromycin, grepafloxacin, ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin and nevirapine; beta blockers, such as propranolol, metoprolol, bisoprolol and nebivolol; antidiabetics, such as metformin, miglitol and repaglinide; H 1 antihistamines
- the film coatings also dissolve relatively quickly in media with pH values of 4.5, meaning that the administration forms produced therefrom develop a rapid effect even in anacidic patients or patients which are treated with antacids.
- These exceptional application properties of the coating compositions are also retained after the conversion to powders and redispersion or melting of the powders.
- polymer A was a polymer referred to as polymer A.
- the preparation of polymer A was carried out analogously to example 1 WO 2009/016258.
- Polymer A methyl methacrylate/diethylaminoethyl methacrylate, weight ratio 55:45, K value 49, Tg 57° C.
- the K value was measured at 0.1% strength by weight in NMP.
- the polymer was used as aqueous dispersion with a pH of 9+/ ⁇ 0.3 or used as spray-dried powder.
- the average particle size of the primary dispersion was 127 nm.
- the glass transition temperatures were determined by means of DSC at a heating rate of 20° K./min. The minimum film-forming temperature corresponded to the Tg within the scope of the measurement accuracy of plus/minus 5° C.
- the D(4,3) value was determined by means of light diffraction using a Malvern Mastersizer 2000.
- the value was determined using a “Malvern Zetasizer nano S” as Z-Average value.
- Ludipress® free-flowing granules comprising 94.4% by weight of lactose, 3.2% by weight of Kollidon 30 (USP) and 3.4% by weight of Kollidon CL (USP)
- the preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied to tablet cores by spraying.
- composition Composition [%] [mg] Caffeine, gran. 0.2-0.5 mm 15.15 50 Ludipress 72.43 239 Avicel PH 101 12.12 40 Magnesium stearate 0.3 1 100.00 330
- the weighed constituents caffeine, Ludipress and Avicel PH 101 were mixed in a Diosna mixer for 3 minutes at stage 1. After adding magnesium stearate, mixing was carried out for a further 1 minute. The powder mixture prepared in this way was compressed on a rotary press to give tablets with a weight of 330 mg and a breaking strength of 80 N.
- the resistance of the tablets was determined after 30, 60, 90 and 120 min.
- the tablets produced in this way exhibited no resistance in buffer pH 6.8.
- the average particle size of the powder was 35 ⁇ m.
- the powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 180 nm.
- the average particle size of the powder was 34 ⁇ m.
- the powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 170 nm.
- the average particle size of the powder was ca. 32 ⁇ m.
- the powder was redispersed analogously to example 1 and exhibited a bimodal distribution of the particle sizes with a maximum both at 197 nm and at 520 nm.
- composition [%] [mg] Propranolol-HCl 13.4 40.0 Ludipress ® 40.2 120.7 Avicel ® PH 102 40.2 120.7 Kollidon ® VA 64 5.2 15.6 Magnesium stearate 1.0 3.0 100.00 300
- the weighed constituents propranolol-HCl, Ludipress, Avicel PH 102 and Kollidon VA 64 were mixed in a Diosna mixer for 3 minutes at stage 1. After adding magnesium stearate, mixing was carried out for a further 1 minute. The powder mixture prepared in this way was compressed on a rotary press to give tablets with a weight of 300 mg and a breaking strength of 85 N.
- the film tablets produced in this way exhibited no resistance in buffer pH 6.8.
- the average particle size of the powder was ca. 37 ⁇ m.
- the powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 192 nm.
- the average particle size of the powder was ca. 32 ⁇ m.
- the powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 178 nm.
- the average particle size of the powder was ca. 43 ⁇ m.
- the powder was redispersed analogously to example 1.
- the measurement of the distribution revealed no result since the redispersion was completely unsatisfactory.
- the average particle size of the powder was ca. 41 ⁇ m.
- the powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 191 nm.
- composition Composition [%] [mg] Quinine hydrochloride 30.30 100.00 dihydrate Ludipress 57.27 189.00 Avicel PH 102 12.02 39.67 Aerosil ® 200 0.11 0.33 Magnesium stearate 0.30 1.00 100.00 330
- the weighed constituents quinine HCl, Ludipress, Avicel PH 102 and Aerosil 200 were mixed in a Diosna mixer for 3 minutes at stage 1. After adding magnesium stearate, mixing was carried out for a further 1 minute. The powder mixture prepared in this way was compacted on a rotary press to give tablets with a weight of 330 mg and a breaking strength of 80 N.
- the average particle size of the powder was ca. 39 ⁇ m.
- the powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 183 nm.
- the spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 175 nm.
- the spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 172 nm.
- the spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 188 nm.
- the spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring using a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 175 nm.
- the preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied to caffeine pellets by spraying analogously to example 1.
- composition of pellets Composition [% by weight] Caffeine 20.0 Lactose 38.5 Microcrystalline 38.5 Kollidon ® CL-F 3.0 100.00
- the constituents were mixed in a Diosna mixer for 3 min and then wetted with water. This wet mass was extruded and then rounded in a rounding machine to give pellets with a diameter of 0.7-1.4 mm.
- the spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring using a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 172 nm.
- the preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to theophyllin granules (particle size from 0.2-0.7 mm) analogously to example 1.
- the spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 188 nm.
- the preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to paracetamol crystals (diameter 0.3 mm) analogously to example 1 by spraying.
- the average particle size of the powder was 37 ⁇ m.
- 750 g of the spray-dried powder was redispersed in demin. water to give a spray suspension with 20% by weight solids content by stirring for 60 minutes using a propeller stirrer. Measurement of the particle size by means of light scattering showed a monomodal distribution with a maximum at 173 nm.
- the spray suspension was admixed with 13% by weight of tributyl citrate based on solid polymer and, after stirring for two hours, further processed with the parameters listed in table 5.
- the average particle size of the powder was 35 ⁇ m.
- Powder A was mixed with powder B in a Turbula such that a degree of neutralization of 7 mol % was established and then redispersed in demin. water with stirring using paddle stirrers to give a 20% strength by weight dispersion.
- This solution was incorporated, with stirring, into 1300 ml of an aqueous dispersion of the polymer with a solids content of 30% by weight such that a degree of neutralization of 7 mol % was established.
- the spray suspension prepared in this way was spray-dried in a FSD spray tower, the atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.3 MPa.
- the inlet air temperature was 118° C. and the outlet air temperature was 63° C.
- the fines fraction was separated off during the spray drying and blown again in front of the spray nozzle such that spray-dried particles with an average particle size of 263 ⁇ m resulted.
- the preparation prepared in this way was admixed with 15% by weight of acetyl triethyl citrate based on solid polymer, stirred for two hours and applied analogously to example 19 by spraying to tablet cores as per table 4.
- the preparation prepared in this way was admixed with 15% by weight of acetyl triethyl citrate based on solid polymer, stirred for two hours and applied analogously to example 1 by spraying to tablet cores as per table 3.
- the preparation prepared in this way was admixed with 15% by weight of acetyl triethyl citrate based on solid polymer, stirred for two hours and applied analogously to example 1 by spraying to tablet cores as per table 1.
- talc and 8 g of indigotin lake were suspended in 500 g of demin. water and then applied to 500 g of polymer powder prepared according to example 12 in a fluidized-bed process.
- the average particle size of the granules was ca. 312 ⁇ m.
- the average particle size of the granules was 298 ⁇ m.
- the coated tablets exhibited a resistance of 83% after 60 min.
- talc 100 g of talc, 20 g of iron oxide red and 5.2 g of malonic acid were suspended in 300 g of demin. water and then homogenized by means of an Ultra-Turrax for 15 min at 10 000 rpm.
- This pigment suspension was incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight.
- the spray suspension prepared in this way and having a degree of neutralization of 7 mol % was then spray-dried in a SBD spray tower, atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.30 MPa.
- the inlet air temperature was 135° C. and the outlet air temperature 63° C.
- the fines fraction was separated off during the spray-drying and blown again in front of the spray nozzle such that spray-dried particles with an average particle size of 320 ⁇ m resulted.
- the spray-dried product was incorporated in water to give a spray suspension with a solids content of 20% by weight by stirring using a paddle stirrer.
- the preparation prepared in this way was admixed with 15% triethyl citrate based on solid polymer, stirred for a further two hours and applied by spraying to tablet cores (table 1) analogously to example 1.
- coated tablets with an application amount of 4 mg/cm 2 exhibited a resistance of 100% after 60 min in buffer pH 6.8.
- 100 g of polymer powder prepared according to example 13 were mixed with 50 g of very finely ground talc, 4 g of indigotin lake and 2.3 g of sebacic acid in a Turbula mixer.
- the suspension was admixed with 15% by weight of dibutyl sebacate and, after stirring for two hours, sprayed analogously to example 19 onto tablets according to table 1.
- the coated tablets exhibited a resistance of 83% after 60 min.
- This powder was mixed with 8.4 g of finely powdered adipic acid, 60 g of fine talc, 2 g of fine xanthan, 15 g of fine iron oxide red and then redispersed with stirring in water to give a spray suspension with 20% solids content by stirring using a paddle stirrer for 60 min.
- Measurement of the particle size by means of light scattering produced a value of 168 nm, talc and iron oxide having been centrifuged off beforehand for this determination.
- the preparation prepared in this way was admixed with 15% by weight of triethyl citrate, based on solid polymer, stirred for two hours and applied analogously to example 19 by spraying onto tablet cores according to table 1.
- the preparation prepared in this way was admixed with 35 g of acetyl triethyl citrate, stirred for two hours and applied analogously to example 1 by spraying onto tablet cores according to table 3.
- the average particle size of the powder was 37 ⁇ m.
- the powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 182 nm.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
Pharmaceutical coatings obtained from coating compositions based on film-forming copolymers of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, where the copolymers are present partially neutralized with C3-C10-dicarboxylic acids.
Description
- This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/608,655, filed Mar. 9, 2012, the entire content of which is incorporated herein by reference in its entirety
- The present invention relates to pharmaceutical protective coatings with good resistance in a neutral environment, where, for the purpose of odor masking or for protecting against moisture, pharmaceutical dosage forms are provided with a film coating based on a cationic copolymer present in partially neutralized form which is obtained by means of free-radical emulsion polymerization of a monomer mixture comprising N,N-diethylaminoethyl methacrylate. The present invention also relates to the production of corresponding coatings and use of corresponding coating compositions for producing protective coatings with good resistance in a neutral environment.
- When producing pharmaceutical dosage forms of unpleasant tasting active ingredients, there is the fundamental problem of providing the dosage forms with coatings which, on the one hand, permit good taste masking in the neutral environment of the oral cavity, but on the other hand do not have excessively large layer thicknesses. This problem also arises in the production of coated drug forms which are provided with protective coatings for the purpose of protecting moisture-sensitive active ingredients.
- Excessively thick coatings are not only esthetically unsatisfactory, because they are more rough than beautifully smooth, but also economically unsatisfactory because more coating composition is required to produce greater layer thicknesses and, moreover, the processing times are longer. Added to this is the fact that excessively thick coatings cause an undesired slower release of the active ingredient in the acidic environment of the stomach, where they are supposed to release the active ingredient as quickly as possible. The aim when developing coating compositions will therefore always be to produce the thinnest possible film coatings, although these have to satisfy the functional demands, as in the present case of taste masking. Desirable application amounts are therefore usually in the range from 1 to 20 mg/cm2.
- The coatings also have to be stable for an adequate time in respect of the taste masking. Especially in the case of dosage forms which disintegrate rapidly in the mouth (so-called “Oral Dispersible Tablets”), in which active ingredient crystals or active ingredient micropellets provided with a taste-masked coating are embedded into a matrix which disintegrates rapidly in the oral environment, it often arises that the coated active ingredient crystals or micropellets get caught up in interdental spaces for a while. If the coating then has inadequate denseness to disintegration in the neutral environment of the oral cavity, then unpleasant taste sensations can occur as a result. The requirement placed on suitable coatings is therefore adequate resistance to release of the active ingredient at neutral pH values of at least one hour, preferably even of two hours.
- A further requirement is the good redispersibility in water of the film-forming polymers which form the basis of the coating compositions used. The film-forming polymers used for the taste masking are usually pH-dependent soluble polymers which are water-insoluble in a neutral environment, but in most cases dissolve rapidly in the acidic environment of the stomach in order to facilitate a rapid release of the active ingredient.
- For the provision of binders for drug coatings with a low residual monomer content, DE-B 2512238 teaches the use of a powder obtained by spray-drying a polymer dispersion for producing coating solutions for these drug forms. As regards the dispersions used for the spray-drying, reference is made to DE 1090381, DE 1219175 and DE 2135073.
- DE 3049179 A1 is an application of addition to DE 2512238 and relates to the use of a powder obtained by spray-drying according to the teaching of the last-mentioned document in the form of an aqueous suspension which additionally comprises a plasticizer for producing coatings by thermogelation.
- WO 00/05307 deals with the provision of coatings and binders for drug forms which comprise (meth)acrylate copolymers which have monomer radicals with tertiary amino groups, the intention being for simple dry or aqueous further processing to be possible.
- WO 02/067906 relates to coating and binding compositions having improved water-vapor permeability compared with those described in WO 00/05307. Here, the coating and binding compositions are produced using a mixture which comprises (a) a copolymer of C1-C4-esters of (meth)acrylic acid and further (meth)acrylate monomers with functional tertiary ammonium groups in powder form having an average particle size from 1 to 40 μm, (b) an emulsifier with an HLB value of at least 14 and (c) a C12-C18-monocarboxylic acid or a C12-C18-hydroxyl compound.
- WO 2004/019918 describes coating and binding compositions which correspond to those described in WO 00/05307 and WO 02/067906 as regards their composition.
- EP88951 A2 describes a process for coating drugs using a water-dispersed coating composition based on emulsion polymers, where the coating compositions may be partially present in salt form. The coating compositions can also be obtained from redispersed powders.
- WO 97/42255 describes the spray-drying of polymer powders that can be redispersed in aqueous solution and comprise free acid- or base-carrying copolymers, where, before the spray drying, the pH values of the dispersions have to be adjusted with the help of a buffer system.
- EP 262326 A2 describes a process for producing a redispersible plastics powder.
- WO 2009/016258 discloses the production of the aqueous polymer dispersions of cationic polymers based on N,N-diethylaminoethyl methacrylate as are used according to the invention and the use thereof for the coating of drugs. Although it is described that the cationic polymers can be partially neutralized a series of inorganic and organic acids is listed quite generally as being suitable for the partial neutralization.
- With the coating compositions known hitherto which are present in partially neutralized form, however, there is the problem that the dosage forms coated therewith have an unsatisfactory resistance to premature disintegration in the neutral environment of the oral cavity. The redispersibility is often also unsatisfactory.
- Embodiments of the present invention to provide coating compositions which impart good resistance to premature active ingredient release to a pharmaceutical dosage form, and at the same time also have a good redispersibility in water.
- Accordingly, pharmaceutical film-forming coatings obtained from coating compositions based on copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in the weight ratio of the monomers of 35:65 to 55:45, where the copolymers are present partially neutralized with C3-C10-dicarboxylic acids, have been found.
- According to one preferred embodiment, the coating compositions are applied in application amounts of 1 to 20 mg/cm2, and in the case of an application amount of 4 mg/cm2, the coatings have a resistance to release of the active ingredient in the aqueous environment at pH 6.8 of at least 80% after 30 min.
- Furthermore, a method for producing coating compositions for coatings of dosage forms comprising at least one pharmaceutical active ingredient with a resistance to premature release of the active ingredient has been found, where the coating compositions comprise, as film-forming polymers, copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in the weight ratio of the monomers of 35:65 to 55:45, wherein the copolymers in the coating composition are partially neutralized with C3-C10-dicarboxylic acids.
- According to a preferred embodiment, the coating compositions are obtained in powder form and redispersed in water prior to application to the dosage form.
- Furthermore, the use of film-forming coating compositions for pharmaceutical dosage forms based on copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in the weight ratio of the monomers of 35:65 to 55:45, where the copolymers are present partially neutralized with C3-C10-dicarboxylic acids, for protecting active ingredient-containing pharmaceutical dosage forms against premature active ingredient release in an aqueous environment at pH 6.8 has been found.
- The resistance to premature release of the pharmaceutical active ingredient in an aqueous environment at pH values in the region of 6.8 is determined with the help of the so-called “paddle model”. This measurement method is described in the USP. For this, the coated dosage forms are tested in phosphate buffer at pH 6.8+/−0.05 with the help of a so-called “paddle apparatus” (apparatus 2) according to USP. The phosphate buffer is prepared by dissolving 34.025 g of potassium dihydrogen phosphate in water in a calibrated 5 l measuring flask, adding 112 ml of 1 molar NaOH and topping up to the calibration mark of the 5 l measuring flask.
- Coatings according to the invention satisfy the criterion that, for an application amount of 4 mg/cm2, they have a resistance to release of the active ingredient in an aqueous environment at pH 6.8 of at least 80% after 30 min.
- Measurement takes place under atmospheric pressure at 25° C. The release of the active ingredient takes place by photometric determination. The release is determined at intervals of 30 min.
- According to the invention, a resistance of 80% after 30 min means that, after 30 min, not more than 20% of the active ingredient has been released. Preferably, the resistance after 30 min is 100%, which means that, within this period, no detectable amounts (less than 2%) of active ingredient are released from the dosage forms. After 60 min, the resistance at pH 6.8 should be at least 60%.
- Dicarboxylic acids suitable according to the invention have a chain length of from 3 to 10 carbon atoms. Suitable dicarboxylic acids are, in particular, unbranched dicarboxylic acids which have terminal acid groups. Suitable dicarboxylic acids are also those which are substituted with one or two hydroxy groups.
- According to the invention, for the purposes of the partial neutralization, preference is given to using dicarboxylic acids which have a first pKa value of greater than 2 and a second pKa value of greater than 4. Particular preference is given to using dicarboxylic acids which have a first pKa value of greater than 2.5 and a second pKa value of greater than 5. The pKa value is the negative base ten logarithm of the acid constant, where the acid constant at 25° C. and atmospheric pressure is intended.
- Suitable dicarboxylic acids which carry no further substituents besides the acid groups are the saturated alkanedicarboxylic acids malonic acid, succinic acid, glutaric acid, adipic acid or sebacic acid. Suitable alkanedicarboxylic acids substituted with one or two hydroxy groups are malic acid (2-hydroxysuccinic acid) or tartaric acid (2,3-dihydroxysuccinic acid). A suitable unsaturated dicarboxylic acid is primarily fumaric acid.
- It is also possible to use mixtures of such dicarboxylic acids. Thus, it may be recommended to mix dicarboxylic acids which produce a particularly good resistance of the coatings with those acids which produce a particularly good redispersibility of the powders. Suitable mixtures are e.g. adipic acid with sulfuric acid or succinic acid with oxalic acid.
- Partial neutralization within the context of the invention means that 2 to 15, preferably 4 to 10 mol % of the diethylaminoethyl groups are present in salt form.
- With respect to the preparation of the copolymers of methyl methacrylate and N,N-diethylaminoethyl methacrylate serving as film formers in the coatings by emulsion polymerization, reference is made expressly to the disclosure in WO 2009/016258.
- The copolymers present in the dispersions preferably have a K value (determined in accordance with Fikentscher on a 1% strength solution in N-methylpyrrolidone (NMP)) in the range from 40 to 60.
- The glass transition temperature TG determined by means of DSC “Differential Scanning calorimetry” is preferably in a range from 40 to 70° C., particularly preferably 52 to 62° C. Here, the samples are firstly heated to 150° C. and then rapidly cooled from 150° C. The measurement of the glass transition temperature takes place at a heating rate of 20° K/min. The minimum film-forming temperature is determined in accordance with the method described in DIN ISO 2115 and is in the range from 40 to 70° C., preferably 50 to 65° C. The measurement accuracy of the method is in the region of plus/minus 5° C.
- The copolymers present in the dispersions are essentially random copolymers.
- The average particle diameter of the polymer particles present in the polymer dispersion (determined by means of analytical ultracentrifuge) is preferably in a range from 70 to 200 nm, particularly preferably from 80 to 150 nm, in particular from 90 to 130 nm. The particle size distribution is preferably essentially unimodal.
- The LT value of the aqueous dispersions used according to the invention, determined on a 0.01% strength dispersion in water (2.5 cm cuvette, white light), is preferably at least 70%, particularly preferably at least 80%. The determination of the light transmission is described e.g. in Dieter Distler, Wässrige Polymerdispersionen [Aqueous polymer dispersions], Wiley-VCH (1999), p. 40.
- Particular preference is given to a copolymer which has a weight ratio of methyl methacrylate (MMA) to diethylaminoethyl methacrylate (DEAEMA) of 55:45. Such a copolymer is also commercially available as Kollicoat® Smartseal, BASF SE.
- According to the invention, the C3-C10-dicarboxylic acids specified at the start are added to the copolymer power or to the corresponding aqueous dispersion. Preferably, amounts of acid are added such that the basic groups are present partially in the form of the acid salts. Thus, 1 to 20 mol % of the basic groups can be present in salt form, preferably 2 to 15 mol %, particularly preferably 5 to 10 mol % of the basic groups are neutralized.
- The partial neutralization of the copolymer of MMA/DEAMA can take place either in the aqueous primary dispersion, or else on the powder or during or after aqueous redispersion of a powder. The copolymer in powder form can be obtained by spraying processes or by freeze-drying.
- Thus, for example, the dicarboxylic acids can be added to the aqueous polymer dispersion prior to a spray-drying. If the acid is incorporated prior to the spray drying, then this can be stirred into the aqueous dispersion using customary methods. According to a further embodiment, a partially neutralized aqueous primary dispersion can be converted to the powder form by freeze-drying.
- According to another embodiment, the acid can also be added before or during the redispersion of a powder produced beforehand from the primary dispersion. In the case of addition to a powder, the incorporation of the acid into the polymer powder can take place such that firstly the polymer powder is coarsely predispersed by means of a simple stirrer, then the acid is added and complete redispersion is achieved by means of further stirring. The redispersion is usually very rapid and, after just 10 min, finely divided dispersates are present. In a modified procedure, it is also possible to firstly introduced the acid in water as initial charge and to add the polymer powder to this with stirring. According to a further embodiment of the invention, the polymer powder and the acid are firstly mixed and this powder mixture is introduced into water. According to this embodiment, a completely neutralized polymer powder can also firstly be prepared, which is then adjusted to the desired degree of partial neutralization by mixing with an unneutralized polymer powder.
- The amounts by weight of acids to be used in individual cases is governed by the particular molecular weight of the C3-C10-dicarboxylic acid and the desired degree of neutralization.
- Preferably, the treatment with acids is carried out such that the pH of the aqueous dispersion, of the powder or of the powder redispersed in water is in the range from 5 to 9.
- Particularly preferably, the addition of the acid or of the acidic salt is added such that the pH of the aqueous dispersion, of the powder or of the water-redispersed powder is in the range from 6 to 8.
- As already mentioned, embodiments of the invention relate to the partial neutralization of the copolymers of MMA/DEAMA in powder form. Preferred procedures for producing the powder form of the copolymers are spraying processes.
- The solids content of the dispersions used according to the invention for the spraying processes is preferably 10 to 50% by weight, particularly preferably 20 to 40% by weight. In the case of a prior purification of the dispersion by means of ultrafiltration, the dispersions used according to the invention preferably have solids contents which are within these ranges before and after the ultrafiltration. It is of course likewise possible to subject a diluted polymer dispersion to a concentration by ultrafiltration prior to the spraying process.
- Preferably, the coating compositions used for producing the coatings according to the invention are obtained by redispersion in water, the powder obtained by a spraying process being redispersed using low-shear stirring apparatuses at revolutions up to 1000 rpm. Surprisingly, it is also possible to use high-shear dispersing apparatuses at revolutions of >5000 rpm. This can take place according to the invention without the fine particles formed during the redispersion agglomerating and the preparation coagulating.
- The average particle size of the polymer powder redispersed in water is at most 5 times, preferably at most 3 times, particularly preferably at most 2 times, that of the underlying primary dispersion.
- Average particle sizes refer here to the Z-Average value, which is determined by light scattering by means of a “Malvern Zetasizer nano S” as Z-Average value.
- Coating compositions can be prepared e.g. by intimately mixing a by redispersing the polymer powder obtained according to the invention to give an aqueous polymer dispersion, to which preferably at least one further auxiliary is added.
- Conversion of the aqueous polymer dispersions to the powder form can take place by means of spraying processes. Suitable spraying processes are in principle spray-drying, agglomerating spray-drying, spray granulation (spray fluidized-bed drying) or spray agglomeration.
- The conditions specified below for carrying out the atomization and drying refer to all embodiments of the spraying process which can be carried out in principle, whether normal spray drying, spray granulation or agglomerating spray drying.
- The atomization preferably takes place as hydrodynamic atomization as a result of liquid pressure or air pressure via nozzles such as, for example, single-material or multiple-material nozzles or via atomizing disks.
- Suitable spraying devices are conventional spray towers into which the polymer dispersion to be atomized is introduced from above. The polymer powders obtained can be discharged at the lower end and be separated off from the drying-gas stream in a downstream cyclone.
- Drying gases which can be used are air or inert gases such as nitrogen, argon or helium. The drying gases can be introduced countercurrently or cocurrently to the liquid droplets produced by the atomization through the spraying apparatus. The drying gas is preferably used cocurrently. The entry temperature of the drying gas is kept at least 20° C., preferably at least 40° C., above the glass transition temperature and, according to one embodiment, also at least 20° C., preferably at least 40° C., above the dynamic freezing temperature and at least 20° C., preferably at least 40° C., above the minimum film-forming temperature of the polymer. The entry temperature of the drying gas into the spraying apparatus is particularly preferably kept at 100 to 140° C. and the exit temperature of the drying gas from the spraying apparatus is kept at 45 to 70° C. Very particularly preferably, the entry temperature of the drying gas into the spraying apparatus is kept at 110 to 130° C. and the exit temperature of the drying gas from the spraying device is kept at 50 to 60° C. The exit temperature of the drying gas is very particularly preferably in the same temperature range plus/minus 5° C. as the minimum film-forming temperature.
- The evaporation of the water in the spraying apparatus can take place either at atmospheric pressure or at 0.06 to 0.12 MPa.
- While carrying out the spraying processes, polymeric spraying auxiliaries such as polyvinyl alcohols, mixtures of polyvinyl alcohol and a graft polymer of polyethylene glycol as graft base and polyvinyl alcohol side chains (commercially available as Kollicoat® Protect), polyvinylpyrrolidones, alkylated and/or hydroxyalkylated celluloses, starch derivatives, lignosulfonates, polyacrylic acids or polyacrylamides can also be added to the aqueous polymer dispersions. Suitable amounts of such spraying auxiliaries are in the range from 0.1 to 30, preferably 1 to 10% by weight, based on the solids content.
- Furthermore, antiblocking agents can also be added to the aqueous polymer dispersions. Suitable antiblocking agents are e.g. aluminum silicates such as bentonite, also kieselguhr, colloidal silica, precipitated silica, diatomaceous earth, calcium carbonate, titanium dioxide, zinc oxide, magnesium silicates such as talc or tricalcium phosphate. Suitable amounts of such antiblocking agents are in the range from 0.1 to 15, preferably 0.5 to 5% by weight, based on the solids content.
- In principle, customary coating auxiliaries can also be added to the aqueous polymer dispersions. Suitable auxiliaries may be: aroma substances, taste-improving substances, sweetening agents (sugars, sugar alcohols, sweeteners such as e.g. aspartame, saccharine-Na, sodium cyclamate), glidants, wetting agents, release agents, antisticking agents, stabilizers, antioxidants, pore formers, neutralizers, luster agents, dyes, pigments, disinfectants or preservatives, thickeners or plasticizers. Suitable auxiliaries are described e.g. in Fiedler, H. P. Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete [Lexicon of Auxiliaries for Pharmacy, Cosmetics and Related Fields], 4th edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.
- Furthermore, the conversion to powder can take place by means of a spray granulation. For this, the aqueous polymer dispersion to be dried is likewise atomized and the droplets produced then come into contact in a fluidized bed with seed particles that have been introduced as initial charge. As a result of this bringing of the seed particles into contact with the droplets of the aqueous polymer dispersion, the seed particles grow to give larger granule particles, with the formation of an onion-peel-like structure around the particle used as seed material.
- Conversion to the powder form can also take place with the help of agglomerating spray drying. Here, the polymer dispersion is atomized in a spray tower as described above, where fine dust which is removed from the drying zone is at the same time blown into the atomizing zone, in which the aqueous polymer dispersion is present in the form of fine droplets. The fine dust particles stick together here to give relatively large aggregates with a blackberry-like structure. Additionally, a fluidized bed can also be connected, in which the water content of the particles formed can be further reduced. The resulting aggregates can have particle sizes of from 150 to 1000 μm, preferably from 200 to 500 μm. In this embodiment too, the entry temperature is selected at least 20° C. and preferably at least 40° C. above the glass transition temperature and, according to one embodiment, also at least 20° C., preferably at least 40° C., above the dynamic freezing temperature and at least 20° C., preferably at least 40° C., above the minimum film-forming temperature of the polymer, and the exit temperature of the drying gas from the spraying apparatus is 40 to 85° C., preferably 45 to 70° C. Preferably, the entry temperature of the drying gas into the spraying apparatus is kept at 100 to 140° C. and the exit temperature of the drying gas from the spraying apparatus is kept at 45 to 70° C. Particularly preferably, the entry temperature of the drying gas into the spraying apparatus is kept at 110 to 130° C. and the exit temperature of the drying gas from the spraying apparatus is kept at 50 to 60° C. The blackberry-like structures obtained by spray agglomeration are virtually dust-free and exhibit a particularly advantageous behavior upon redispersion.
- In all of the embodiments specified above, spraying auxiliaries such as e.g. aluminum silicates such as bentonite, kieselguhr, colloidal silica, precipitated silica, diatomaceous earth, calcium carbonate, titanium dioxide, zinc oxide, magnesium silicates such as talc or tricalcium phosphate can be blown into the spray tower during the spraying process in amounts of from 0.1 to 15, preferably 0.5 to 5% by weight, based on the polymer powder.
- Overall, the particle sizes of the powder formed by spraying processes are governed by the particular variant. In the case of a normal spray drying, particle sizes of from 10 to 150 μm can be achieved. In the case of a spray granulation, such as, for example, a spray fluidized-bed drying, larger particle sizes of from 150 up to 1000 μm can be achieved. In the case of agglomerating spray drying, particle sizes of from 150 to 1000 μm can be achieved.
- The copolymers are obtained as free-flowing powders which, for the purposes of the present invention, means that the powders, upon determining the flowability in accordance with DIN ISO 4324 using Pfrengle equipment without stirring aid, flow out of the funnel freely and completely.
- The residual solvent content is usually not more than 5% by weight, based on the solids content of the powder.
- The redispersible copolymer powders to be used according to the invention for producing the coatings have, in water at a solids content of 20% by weight, low viscosities of preferably less than 300 mPas, particularly preferably less than 200 mPas and in particular less than 100 mPas (values determined by means of Brookfield viscometer at 20° C. and 100 s−1). Such viscosities are of particular importance for many applications.
- For the purposes of stabilization, the polymer dispersions can be treated, as mentioned, with sparingly water-soluble antioxidants prior to being converted to the powder form. The term “antioxidants” is known per se to the person skilled in the art (see e.g. Römpp-Lexikon der Chemie [Lexicon of Chemistry], 9th edition, 1989, Georg-Thieme-Verlag, Stuttgart) and refers to substances which are intended to inhibit or prevent undesired changes brought about by oxygen or other oxidative processes. According to the invention, suitable antioxidants for stabilizing the coating compositions are sparingly water-soluble antioxidants, i.e. antioxidants whose solubility in water at 20° C. is not more than 1 g/l.
- In this connection, suitable antioxidants are primarily the lipophilic substances tocopherol, tocopherol acetate, ascorbyl palmitate, ascorbyl stearate, t-butylhydroquinone, t-butylhydroxyanisole, t-butylhydroxytoluene, octyl gallate or dodecyl gallate or combinations thereof.
- Here, the antioxidants used can also be dissolved in an organic solvent. Suitable organic solvents are those solvents which, on the one hand, are miscible with water to a sufficient extent that a concentration of at least 10% by weight in water can be achieved, but, on the other hand, are able to dissolve the sparingly water-soluble antioxidants. Suitable solvents are alcohols such as e.g. ethanol or isopropanol, ketones such as e.g. acetone, methyl ethyl ketone and esters such as e.g. methyl acetate. Usually, these solvents have boiling points below 100° C.
- The antioxidants can be brought into organic solution in a manner customary per se. The concentration is selected such that 10 to 1000 g of antioxidant are used per liter of solvent. In total, the amount of organic solvent is selected such that 1 to 20% by weight of solvent are used, based on the weight of the aqueous dispersion.
- According to a further embodiment, the antioxidants can be incorporated into the aqueous dispersion in the form of an aqueous micellar solution. For this purpose, the substances are brought into solution in the presence of solubilizing substances (“solubilizers”) (as regards the term “solubilization”, see Römpp-Chemielexikon, [Chemistry Lexicon], 9th edition). Suitable solubilizers are surfactants such as e.g. sodium docusate or sodium dodecylsulfate, ethoxylated fats, ethoxylated fatty acids, ethoxylated fatty alcohols or polymeric solubilizers.
- Suitable polymeric solubilizers are primarily amphiphilic copolymers. According to the invention, amphiphiilic copolymers are understood as meaning copolymers which are composed of hydrophilic and hydrophobic segments. The segments can also have a LCST (Lower Critical Solution Temperature). The segments are for their part polymer chains which, on account of their composition and/or the monomers used for producing the segments, are either hydrophilic or hydrophobic. The amphiphilic copolymers can be block polymers or graft polymers. Besides linear block polymers, the structure of the copolymer can also be comb-like or star-like. In the case of the graft polymers, either hydrophobic side chains and a hydrophilic graft base may be present, or hydrophilic side chains and a hydrophobic graft base. The side chains may either be grafted to or grafted on. Suitable amphiphilic copolymers are disclosed for example in WO 2007/017452, WO 2007/051743, WO 2007/065845 and WO 2007/065846, to the description of which with regard to suitable amphiphilic copolymers and their production reference is hereby made. Further amphiphilic copolymers are for example poloxamers.
- Suitable hydrophilic segments are N-vinyllactam homopolymer or copolymer chains, in particular N-vinylpyrrolidone-containing polymers, as well as polyvinyl alcohol chains or polyethers. Suitable hydrophobic segments are, for example, homopolymers or copolymers of N-vinyl acetate. A suitable comonomer is for example N-vinylcaprolactam. A preferred polymeric solubilizer is a graft polymer commercially available under the name Soluplus®, BASF SE, with PEG 6000 as graft base and a copolymer side chain produced from vinyl acetate and N-vinylcaprolactam. Also of suitability for producing the micellar solution are all surfactants which have an HLB of more than 12. Such surfactants are described in “Fiedler, Encyclopedia of Excipients”, Editio Cantor Verlag. Sixth edition, 2007, pages 112-119. The aqueous antioxidant solubilizates comprise 0.5 to 30% by weight, preferably 1 to 20% by weight, of antioxidant and 1 to 50% by weight, preferably 1 to 30% by weight, of solubilizer. Overall, the amount is selected such that 1 to 40% by weight of aqueous antioxidant solubilizate, based on the weight of the aqueous dispersion, are used.
- Furthermore, the sparingly water-soluble antioxidants can be introduced into the aqueous dispersion of the polymeric coating composition in the form of finely divided aqueous dispersions. In this connection, dispersions is the term used to refer to two-phase systems which may be either solid/liquid (suspensions) or liquid/liquid (emulsions). The average particle size (d4,3) of the antioxidants here should be less than 20 μm, preferably less than 10 μm, particularly preferably less than 3 μm.
- Thus, the antioxidants can be dissolved in emulsifiers and then dispersed in water. However, the antioxidants can also be added directly to water and be dispersed with the aid of emulsifiers using high-shear dispersing tools. Particular preference is given here to heating the preparation to a temperature above the melting point of the antioxidant, as a result of which an emulsion is formed. This hot emulsion can be added directly to the polymer dispersion with stirring. Alternatively, it can also be cooled beforehand, as a result of which a finely divided suspension is formed. It is particularly preferred to add the hot emulsion to a polymer dispersion which likewise has a temperature above the melting point of the antioxidant.
- Suitable emulsifiers are in principle all classes of interface-active substances with an HLB value of >10 (re the Hydrophilic-Lipophilic-Balance value, see Fiedler, Encyclopedia of Excipients, Editio Cantor Verlag Sixth edition, 2007, pages 112-119). Suitable emulsifiers are in principle all ethoxylated fatty acids, ethoxylated fatty alcohols, ethoxylated fatty acid ethers or ethoxylated fatty acid esters with corresponding HLB values. Corresponding ethoxylated sorbitan, stearyl, oleyl, lauryl or palmityl derivatives, for example Solutol® HS (Macrogol 15 hydroxystearate) or ethoxylated hydrogenated castor oil, such as, for example, Cremophor® RH40 (ethoxylated with 40 ethylene oxide units) or the corresponding Eumulgin® grades, for example, are suitable.
- Further suitable emulsifiers are poloxamers (polyethylene oxide-polypropylene oxide block copolymers).
- The aqueous antioxidant/emulsifier dispersions comprise 1 to 50% by weight, preferably 2 to 30% by weight, of antioxidant and 0.1 to 30% by weight, preferably 0.5 to 10% by weight, of emulsifier.
- Overall, the amount is selected such that 1 to 40% by weight of aqueous antioxidant/emulsifier dispersion are used, based on the weight of the aqueous polymer dispersion.
- Furthermore, the antioxidants can be used in the form of a so-called “solid solution”. The term “solid solution” is known to the person skilled in the art and refers to a molecularly disperse distribution of one solid in another solid. In the present case, the antioxidants can be incorporated as solid solutions into a suitable solid solubilizer or into a polymeric protective colloid. The resulting solid solution can then be incorporated directly in solid form into the aqueous coating composition dispersion, or be converted beforehand into a micellar aqueous solution or into a colloidal solution and then be incorporated into the aqueous coating composition dispersion. The solid solutions can for example be produced by dissolving the antioxidants together with the solubilizer or the protective colloid in a suitable solvent and then evaporating the solvent.
- Furthermore, the solid solution of the antioxidants can be prepared by melt extrusion, where antioxidants and solubilizers or polymeric protective colloids are melted together and then extruded, molded and solidified. The granular solid melt extrudates obtained after the extrusion can be incorporated particularly advantageously into the aqueous dispersion of the polymeric coating composition. Suitable matrix polymers and protective colloids for solid solutions here are the amphiphilic copolymers already mentioned, in particular Soluplus®, or poloxamers such as Lutrol® F86, but also nonamphiphilic polymers such as e.g. polyvinylpyrrolidones, vinylpyrrolidone-vinyl acetate copolymers, polyethylene glycols, polyvinyl alcohols, polyvinyl alcohol-polyethylene glycol graft copolymers or hydroxyalkylated celluloses.
- Coating compositions can be produced e.g. by intimately mixing a by redispersing the polymer powder obtained according to the invention to give an aqueous polymer dispersion, to which preferably at least one further auxiliary is added.
- Suitable additional auxiliaries may be: aroma substances, taste-improving substances, sweetening agents (sugars, sugar alcohols, sweeteners such as e.g. aspartame, saccharine-Na, sodium cyclamate), glidants, wetting agents, release agents, antisticking agents, stabilizers, antioxidants, pore formers, neutralizing agents, luster agents, dyes, pigments, disinfectants or preservatives, thickeners, plasticizers etc. Such substances are described e.g. in Fiedler, H. P. Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete [Lexicon of Auxiliaries for Pharmacy, Cosmetics and Related Fields], 4th edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.
- To produce the coating composition, the MMA/DEAEMA polymer powder can be ground prior to redispersion in water. The grinding can also take place in the presence of the specified additional auxiliaries.
- Customary amounts of the auxiliaries are in a range from in each case 0 to 70% by weight, preferably 0 to 60% by weight, in particular 1 to 50% by weight, based on the total weight of the solid of the coating composition.
- According to one embodiment of the invention, the coatings are produced with a coating composition according to the invention in aqueous form. The application of the coating composition can take place in aqueous form by granulation, pouring, spreading or by means of spray application.
- The coating composition obtained according to the invention can also be applied in powder form to the pharmaceutical dosage forms.
- Preferably, the application is as aqueous polymer dispersion obtained by redispersing a pulverulent coating composition according to the invention. In principle, any dispersing apparatus is suitable for the redispersion. Here, the redispersion takes place preferably with the application of low shear forces, preferably by means of a blade, propeller, anchor stirrer or a comparable stirring tool. The polymer powders according to the invention are hereby redispersed spontaneously and rapidly. The redispersion of the polymer powder in water is usually completed in 10 min.
- Further components required for producing the coatings can be added to these redispersed preparations. Such components are in particular plasticizers such as e.g. triethyl citrate, tributyl citrate, diethyl sebacate, dibutyl sebacate, acetyl triethyl citrate.
- The production of the finely dispersed dispersions by redispersing powders can also take place at very high shear forces such as for example in a rotor-stator apparatus, which is also called Ultra-Turrax, or a colloid mill. The introduction of high shear forces is regulated in a rotor-stator apparatus via the number of revolutions of the apparatus. Preferably, the redispersion takes place with the help of a dispersing apparatus at <5000 rpm. This process is particularly advantageous if further coarsely particulate additives or agglomerated additives additionally have to be incorporated into the dispersion which necessitate a special comminution. The separate comminution of these additives in water and subsequent addition to the redispersed polymer powder is thus dispensed with.
- In one particular embodiment, the redispersible polymer powders according to the invention are mixed with further customary coating constituents and/or additives described above to produce so-called ready-to-use preparations which comprise all of the required constituents of a finished coating. These are present in powder or granule form. The user only needs to stir them into water to produce a ready-to-spray suspension. These ready-to-use preparations are produced by dry mixing, grinding, compaction or granulation of the constituents with a granulating liquid, followed by a drying step. Thus, for example, a polymer powder partial neutralized according to the invention can be granulated with an aqueous suspension comprising pigments and optionally further auxiliaries. These granules can then be redispersed to give a spray suspension.
- The coating compositions according to the invention can additionally comprise at least one further polymer component. In this connection, mixtures of at least two dispersions, at least one dispersion and at least one solution, at least one dispersion and at least one powder, at least two powders, etc. can be used.
- Irrespective of the individual embodiments of the invention, the application amount of the coating composition is preferably in the range from 1 to 20 mg/cm2, preferably 2 to 15 mg/cm2, particularly preferably 4 to 12 mg/cm2.
- According to the invention, the coating compositions serve to produce coatings for pharmaceutical dosage forms which are intended to be rapidly releasing in the acidic environment of the stomach, i.e. the coatings according to the invention are soluble in gastric juice. In this connection, rapidly releasing means that at least 80% of the active ingredient has been released after 60 min at 25° C. under atmospheric pressure according to the paddle model (medium: 0.1 N HCl). Coatings obtained according to the invention should not dissolve in the oral cavity and throat in the neutral or almost neutral environment of saliva.
- The coatings according to the invention can be used for taste masking or for protecting against moisture. The water vapour permeability of the coatings is very low, as a result of which active ingredients that are sensitive to moisture are protected.
- Pharmaceutical dosage forms which can be provided with the coatings according to the invention are tablets, capsules or pellets. Furthermore, active ingredient crystals can also be provided with the coatings according to the invention.
- The coating compositions obtained by the process according to the invention are suitable for dosage forms of in principle any desired pharmaceutical active ingredients, which can preferably be administered in isolated or protected form, such as antidepressants, beta receptor blockers, antidiabetic agents, analgesics, antiphlogistics, antirheumatics, antihypotensives, antihypertensives, psychoactive drugs, tranquilizers, antiemetics, muscle relaxants, glucocorticoids, agents for treating ulcerative colitis or Crohn's disease, antiallergic agents, antibiotics, antiepileptics, anticoagulants, antimycotics, antitussives, arteriosclerotic agents, diuretics, enzymes, enzyme inhibitors, gout remedies, hormones and inhibitors thereof, cardiac glycosides, immunotherapeutic agents and cytokines, laxatives, antilipanic agents, gastrointestinal therapeutic agents, antimigrane agents, preparation of mineral substances, otologic agents, agents to treat Parkinson's disease, thyroid therapeutic agents, spasmolytics, platelet aggregation inhibitors, vitamins, cytostatics and metastasis inhibitors, phytopharmaceuticals, chemotherapy agents, nutraceuticals, vitamins, carotenoids and amino acids.
- Examples of suitable active ingredients are: acarbose, nonsteroidal antirheumatics, cardiac glycosides, acetylsalicylic acid, virustatic agents, aclarubicin, aciclovir, cisplatin, actinomycin, α- and β-sympathomimetics, allopurinol, alosetron, alprostadil, prostaglandins, amantadine, ambroxol, amlodipine, methotrexate, 5-aminosalicylic acid, amitriptyline, amlodipine, amoxicillin, anastrozole, atenolol, atorvastatin, azathioprine, balsalazide, beclomethasone, betahistine, bezafibrate, bicalutamide, diazepam and diazepam derivatives, budesonide, bufexamac, buprenorphine, methadone, calcium salts, potassium salts, magnesium salts, candesartan, carbamazepine, captopril, cephalosporins, celetoxib, cetirizine, chenodeoxycholic acid, ursodeoxycholic acid, theophylline and theophylline derivatives, trypsin, cimetidine, clarithromycin, clavulanic acid, clindamycin, clobutinol, clonidine, cotrimoxazole, codeine, caffeine, vitamin D and derivatives of vitamin D, colestyramine, cromoglycic acid, coumarin and coumarin derivatives, cysteine, cytarabine, cyclophosphamide, cyclosporin, cyproterone, cytarabine, dapiprazole, desogestrel, desonide, dihydralazine, diltiazem, ergot alkaloids, dimenhydrinate, dimethylsulfoxide, dimeticone, dipyridamole, domperidone and domperidone derivatives, donepzil, dopamine, doxazosin, doxorubicin, doxylamine, dapiprazole, benzodiazepine, diclofenac, glycoside antibiotics, desipramine, econazole, ACE inhibitors, enalapril, ephedrine, epinephrin, epoetin and epoetin derivatives, morphinanes, calcium antagonists, irinotecan, modafinil, orlistat, peptide antibiotics, phenyloin, riluzole, risedronate, sildenafil, topiramate, macrolide antibiotics, esomeprazole, estrogen and estrogen derivatives, gestagen and gestagen derivatives, testosterone and testosterone derivatives, androgen and androgen derivatives, ethenzamide, etofenamate, etofibrate, fenofibrate, etofylline, etoposide, famciclovir, famotidine, felodipine, fenofibrate, fentanyl, fenticonazole, gyrase inhibitors, fluconazole, fludarabine, flunarizine, fluorouracil, fluoxetine, flurbiprofen, ibuprofen, flutamide, fluvastatin, follitropin, formoterol, fosfomycin, furosemide, fusidic acid, galantamine, gallopamil, ganciclovir, gemfibrozil, gentamicin, ginkgo, St. John's wort, glibenclamide, urea derivatives as oral antidiabetics, glucagon, glucosamine and glucosamine derivatives, glutathione, glycerol and glycerol derivatives, hypothalamus hormones, goserelin, guanethidine, halofantrine, haloperidol, heparin and heparin derivatives, hyaluronic acid, hydralazine, hydrochlorothiazide and hydrochlorothiazide derivatives, salicylates, hydroxyzine, idarubicin, ifosfamide, imipramine, indometacin, indoramin, insulin, interferons, iodine and iodine derivatives, isoconazole, isoprenaline, glucitol and glucitol derivatives, itraconazole, ketoconazole, ketoprofen, ketotifen, lacidipine, lansoprazole, levodopa, levomethadone, thyroid hormones, lipoic acid and lipoic acid derivatives, lisinopril, lisuride, lofepramine, lomustine, loperamide, loratadine, maprotiline, mebendazole, mebeverine, meclozine, mefenamic acid, mefloquine, meloxicam, mepindolol, meprobamate, meropenem, mesalazine, mesuximide, metamizole, metformin, methotrexate, methylphenidate, methylprednisolone, metixene, metoclopramide, metoprolol, metronidazole, mianserin, miconazole, minocycline, minoxidil, misoprostol, mitomycin, mizolastine, moexipril, morphine and morphine derivatives; evening primrose, nalbuphine, naloxone, tilidine, naproxen, narcotine, natamycin, neostigmine, nicergoline, nicethamide, nifedipine, niflumic acid, nimodipine, nimorazole, nimustine, nisoldipine, adrenaline and adrenaline derivatives, norfloxacin, novamine sulfone, noscapine, nystatin, ofloxacin, olanzapine, olsalazine, omeprazole, omoconazole, ondansetron, orlistat, oseltamivir, oxaceprol, oxacillin, oxiconazole, oxymetazoline, pantoprazole, paracetamol, paroxetine, penciclovir, oral penicillin, pentazocine, pentifylline, pentoxifylline, perphenazine, pethidine, plant extracts, phenazone, pheniramine, barbituric acid derivatives, phenylbutazone, phenyloin, pimozide, pindolol, piperazine, piracetam, pirenzepine, piribedil, piroxicam, pramipexole, pravastatin, prazosin, procaine, promazine, propiverine, propranolol, propyphenazone, prostaglandins, protionamide, proxyphylline, quetiapine, quinapril, quinaprilat, ramipril, ranitidine, reproterol, reserpine, ribavirin, rifampicin, risperidone, ritonavir, ropinirole, rosiglitazone, roxatidine, roxithromycin, ruscogenin, rutoside and rutoside derivatives, sabadilla, salbutamol, salmeterol, scopolamine, selegiline, sertaconazole, sertindole, sertraline, silicates, simvastatin, sitosterol, sotalol, spaglumic acid, sparfloxacin, spectinomycin, spiramycin, spirapril, spironolactone, stavudine, streptomycin, sucralfate, sufentanil, sulbactam, sulfonamides, sulfasalazine, sulpiride, sultamicillin, sultiame, sumatriptan, suxamethonium chloride, tacrine, tacrolimus, taliolol, tamoxifen, taurolidine, tazarotene, tegaserod, temazepam, teniposide, tenoxicam, terazosin, terbinafine, terbutaline, terfenadine, terlipres sin, tertatolol, tetracyclines, tetryzoline, theobromine, theophylline, butizine, thiamazole, phenothiazines, thiotepa, tiagabine, tiapride, propionic acid derivatives, ticlopidine, timolol, tinidazole, tioconazole, thioguanine, thioxolone, tiropramide, tizanidine, tolazoline, tolbutamide, tolcapone, tolnaftate, tolperisone, topotecan, torasemide, antiestrogens, tramadol, tramazoline, trandolapril, tranylcypromine, trapidil, trazodone, triamcinolone and triamcinolone derivatives, triamterene, trifluperidol, trifluridine, trimethoprim, trimipramine, tripelennamine, triprolidine, trifosfamide, tromantadine, trometamol, tropalpine, troxerutin, tulobuterol, tyramine, tyrothricin, urapidil, ursodeoxycholic acid, chenodeoxycholic acid, valaciclovir, valdecoxib, valproic acid, vancomycin, vecuronium chloride, venlafaxine, verapamil, vidarabine, vigabatrin, viloxazine, vinblastine, vincamine, vincristine, vindesine, vinorelbine, vinpocetine, viquidil, warfarin, xantinol nicotinate, xipamide, zafirlukast, zalcitabine, zanamivir, zidovudine, zolmitriptan, zolpidem, zopiclone, zotepine and the like.
- If desired, the active ingredients can also be used in the form of their pharmaceutically acceptable salts or derivatives, and in the case of chiral active ingredients, both optically active isomers and also racemates or diastereoisomer mixtures can be used. If desired, the compositions according to the invention can also comprise two or more pharmaceutical active ingredients.
- According to the invention, the coating compositions can be used for coating extrudates, minitablets, capsules, soft capsules, granules, pellets, micropellets, microcapsules, nanocapsules or crystals.
- For producing dosage forms, the coated granules, pellets, micropellets, microcapsules, crystals can be mixed with suitable auxiliaries and compacted to give tablets, which disintegrate in the aqueous environment of the oral cavity and release the coated fine shaped articles again. Of particular importance in this connection are the so-called oral dispersibles, i.e. tablets which disintegrate in the mouth within a short time and release the taste-masked small shaped articles.
- Furthermore, the coating compositions can also be used advantageously for coating tablets.
- Active ingredient classes and substances which can often bring about an unpleasant bitter taste and can be formulated advantageously according to the invention are e.g.:
- analgesics and antirheumatics, such as paracetamol, diclofenac, aceclofenac, ibuprofen, ketoprofen, flurbiprofen, acetylsalicylic acid, levacetylmethadol and oxycodone; psychoactive drugs, such as promethazines, donepezil, modafinil, nefazodone, reboxetine, sertindole and sertraline;
antibiotics, such as erythromycin, roxithromycin, clarithromycin, grepafloxacin, ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin and nevirapine;
beta blockers, such as propranolol, metoprolol, bisoprolol and nebivolol;
antidiabetics, such as metformin, miglitol and repaglinide;
H1 antihistamines, such as diphenhydramine, fexofenadine and mizolastine;
H2 antihistamines, such as cimetidine, famotidine, roxatidine, nizatidine, ticlopidine, cetirizine and ranitidine;
vitamins such as thiamine nitrate and quinidine sulfate, amyloprilose HCl, pseudoephedrine HCl, sildenafil, topiramate, granisetron, rebamipide, quinine HCl, etc. - Also various salts of these active ingredients can be formulated correspondingly.
- The exceptional taste masking results from the insolubility of the polymers according to the invention at pH values greater than 6 and the rapid solubility at pH values below 6. That is, in the saliva (pH: 7.2) correspondingly coated forms are stable for a very long time and there is no contact between the bitter drug and the oral mucosa, but in the stomach at pH values from 1 to 5 there is very rapid release of the active ingredient. The dissolution is so rapid here that there is no difference in the onset of action compared with an uncoated form. As a rule, film coatings of a polymer according to the invention dissolve within 5 min in gastric juice, whereas in phosphate buffer pH 7.2 they are stable for 2 hours. Surprisingly, the film coatings also dissolve relatively quickly in media with pH values of 4.5, meaning that the administration forms produced therefrom develop a rapid effect even in anacidic patients or patients which are treated with antacids. These exceptional application properties of the coating compositions are also retained after the conversion to powders and redispersion or melting of the powders.
- Glass transition temperature: Tg
Demin. water: demineralized water - In all examples, the polymer used was a polymer referred to as polymer A. The preparation of polymer A was carried out analogously to example 1 WO 2009/016258.
- Polymer A: methyl methacrylate/diethylaminoethyl methacrylate, weight ratio 55:45, K value 49, Tg 57° C.
- The K value was measured at 0.1% strength by weight in NMP. The polymer was used as aqueous dispersion with a pH of 9+/−0.3 or used as spray-dried powder. The average particle size of the primary dispersion was 127 nm. The glass transition temperatures were determined by means of DSC at a heating rate of 20° K./min. The minimum film-forming temperature corresponded to the Tg within the scope of the measurement accuracy of plus/minus 5° C.
- When determining the average particle sizes of the powders, the D(4,3) value was determined by means of light diffraction using a Malvern Mastersizer 2000.
- When determining the average particle sizes of the redispersed powders by means of light scattering, the value was determined using a “Malvern Zetasizer nano S” as Z-Average value.
- Ludipress®: free-flowing granules comprising 94.4% by weight of lactose, 3.2% by weight of Kollidon 30 (USP) and 3.4% by weight of Kollidon CL (USP)
- Avicel® PH102: microcrystalline cellulose, average particle diameter 100 μm
Simethicone: CTFA name for a mixture of dimethicone with an average chain length of 200-350 dimethylsiloxane units and silica gel
Aerosil® 200: finely divided silica - 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight were mixed, with stirring, with 6.5 g of 85% strength by weight phosphoric acid. This corresponds a degree of neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried in a spray tower. Atomization was carried out here via a 1.4 mm two-material nozzle with an atomization pressure of 3.0 bar. The drying gas was passed tangentially in the input area of the spray dryer and the dried product was separated off in a cyclone. The inlet air temperature was 107° C. and the outlet air temperature 56° C. The average particle size of the powder was 30 μm. 100 g of the spray-dried product were dispersed in water to give a spray suspension with 20% solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering showed a bimodal distribution with a maximum both at 130 nm and at 450 nm.
- The preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied to tablet cores by spraying.
-
TABLE 1 Core composition: Composition [%] [mg] Caffeine, gran. 0.2-0.5 mm 15.15 50 Ludipress 72.43 239 Avicel PH 101 12.12 40 Magnesium stearate 0.3 1 100.00 330 - To produce the cores, the weighed constituents caffeine, Ludipress and Avicel PH 101 were mixed in a Diosna mixer for 3 minutes at stage 1. After adding magnesium stearate, mixing was carried out for a further 1 minute. The powder mixture prepared in this way was compressed on a rotary press to give tablets with a weight of 330 mg and a breaking strength of 80 N.
-
TABLE 2 Spraying conditions: Equipment Innojet Ventilus 1 Nozzle: IRN 2 Inlet air temperature 60° C. Inlet air amount 90 m3/h Batch size 150 g Spraying rate 1.5 g/min Spraying pressure 0.15 MPa Application amount 4 mg/cm2 - Testing as to the resistance of the coated tablets in buffer pH 6.8 was carried out by means of six-fold determination in a release apparatus (USP, Apparatus 2).
- The resistance of the tablets (active ingredient release <2%) was determined after 30, 60, 90 and 120 min.
- The tablets produced in this way exhibited no resistance in buffer pH 6.8.
- 5.1 g of oxalic acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %, This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was 35 μm.
- The powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 180 nm.
- Further processing to give film tablets with an application amount of 4 mg/cm2 was carried out analogously to example 1. The tablets produced in this way exhibited no resistance in buffer pH 6.8 despite very good redispersion.
- 6.7 g of succinic acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was 34 μm.
- The powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 170 nm.
- Further processing to give film tablets with an application amount of 4, 8 and 12 mg/cm2 was carried out analogously to example 1.
- Testing the tablets as to resistance in buffer pH 6.8 revealed the following results:
-
4 mg/cm2 8 mg/cm2 12 mg/cm2 30 min 100% 100% 100% 60 min 72% 95% 100% - 12.1 g of sodium dihydrogen citrate were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of a neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was ca. 32 μm.
- The powder was redispersed analogously to example 1 and exhibited a bimodal distribution of the particle sizes with a maximum both at 197 nm and at 520 nm.
-
TABLE 3 Core composition: Composition [%] [mg] Propranolol-HCl 13.4 40.0 Ludipress ® 40.2 120.7 Avicel ® PH 102 40.2 120.7 Kollidon ® VA 64 5.2 15.6 Magnesium stearate 1.0 3.0 100.00 300 - To produce the cores, the weighed constituents propranolol-HCl, Ludipress, Avicel PH 102 and Kollidon VA 64 were mixed in a Diosna mixer for 3 minutes at stage 1. After adding magnesium stearate, mixing was carried out for a further 1 minute. The powder mixture prepared in this way was compressed on a rotary press to give tablets with a weight of 300 mg and a breaking strength of 85 N.
- Further processing to give film tablets with an application amount of 4 mg/cm2 was carried out analogously to example 1.
- The film tablets produced in this way exhibited no resistance in buffer pH 6.8.
- 168.5 ml of 1 molar sulfuric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was ca. 37 μm.
- The powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 192 nm.
- Further processing to give film tablets with an application amount of 4 mg/cm2 was carried out analogously to example 1. The tablets produced in this way surprisingly exhibited no resistance in buffer pH 6.8 despite very good redispersion.
- 7.4 g of glutaric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30%. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was ca. 32 μm.
- The powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 178 nm.
- Further processing to give film tablets with an application amount of 4, 8 and 12 mg/cm2 was carried out analogously to example 1.
- Testing the tablets as to resistance in buffer pH 6.8 revealed the following results:
-
4 mg/cm2 8 mg/cm2 12 mg/cm2 30 min 100% 100% 100% 60 min 68% 91% 100% - 15.9 g of stearic acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30%. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was ca. 43 μm.
- The powder was redispersed analogously to example 1. The measurement of the distribution revealed no result since the redispersion was completely unsatisfactory.
- Further processing to give film tablets was not possible.
- 3.4 ml of acetic acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30%. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was ca. 41 μm.
- The powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 191 nm.
-
TABLE 4 Core composition: Composition [%] [mg] Quinine hydrochloride 30.30 100.00 dihydrate Ludipress 57.27 189.00 Avicel PH 102 12.02 39.67 Aerosil ® 200 0.11 0.33 Magnesium stearate 0.30 1.00 100.00 330 - To produce the cores, the weighed constituents quinine HCl, Ludipress, Avicel PH 102 and Aerosil 200 were mixed in a Diosna mixer for 3 minutes at stage 1. After adding magnesium stearate, mixing was carried out for a further 1 minute. The powder mixture prepared in this way was compacted on a rotary press to give tablets with a weight of 330 mg and a breaking strength of 80 N.
- Further processing to give film tablets with an application amount of 4 mg/cm2 was carried out analogously to example 1. The tablets produced in this way surprisingly exhibited no resistance in buffer pH 6.8 despite very good redispersion.
- 6.5 g of fumaric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30%. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was ca. 39 μm.
- The powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 183 nm.
- Further processing to give film tablets with an application amount of 4, 8 and 12 mg/cm2 was carried out analogously to example 1.
- Testing the tablets as to resistance in buffer pH 6.8 revealed the following results:
-
4 mg/cm2 8 mg/cm2 12 mg/cm2 30 min 100% 100% 100% 60 min 65% 87% 100% - 6.5 g of fumaric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized dispersion was spray-dried in a FSD spray tower, with atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.3 MPa. The inlet air temperature was 110° C. and the outlet air temperature was 57° C. The fines fraction was separated off during the spray drying and blown again in front of the spray nozzle so that spray-dried particles with an average particle size of 280 μm resulted.
- The spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 175 nm.
- The preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to tablet cores (formulation table 1) analogously to example 1.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 71% - 6.7 g of succinic acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized dispersion was spray-dried analogously to example 10 in a FSD spray tower. The average particle size of the powder was 312 μm.
- The spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 172 nm.
- The preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to tablet cores analogously to example 4 (table 3). Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 75% - 7.4 g of glutaric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized dispersion was spray-dried analogously to example 10 in a FSD spray tower. The average particle size of the powder was 295 μm.
- The spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 188 nm.
- The preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to tablet cores analogously to example 8 (table 4). Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 72% - 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight was spray-dried in a FSD spray tower, the atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.3 MPa. The inlet air temperature was 127° C. and the outlet air temperature 59° C. The fines fraction was separated off during the spray drying and blown again in front of the spray nozzle such that spray-dried particles with an average particle size of 220 μm resulted.
- 5.2 g of fumaric acid were dissolved in 1000 ml of demin. water and then 250 g of the spray-dried powder were incorporated with stirring using a paddle stirrer. This corresponds to a degree of neutralization of 8 mol %. After a redispersion time of 60 min, the average particle size was 184 nm.
- The preparation prepared in this way was admixed with 35 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to tablet cores (formulation table 3) analogously to example 1.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 68% - 5.3 g of succinic acid were dissolved in 1000 ml of demin. water and then 250 g of the spray-dried powder from example 13 were incorporated with stirring using a paddle stirrer. This corresponds to a degree of neutralization of 8 mol %. After a redispersion time of 60 min, the average particle size was 165 nm.
- The preparation prepared in this way was admixed with 35 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to tablet cores (formulation table 4) analogously to example 1.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 79% - 5.9 g of glutaric acid were dissolved in 1000 ml of demin. water and then 250 g of the spray-dried powder from example 13 were incorporated with stirring using a paddle stirrer. This corresponds to a degree of neutralization of 8 mol %. After a redispersion time of 60 min, the average particle size was 174 nm.
- The preparation prepared in this way was admixed with 35 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to tablet cores (formulation table 1) analogously to example 1.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 69% - 6.5 g of fumaric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized dispersion was spray-dried analogously to example 10 in a FSD spray tower. The average particle size of the powder was 280 μm.
- The spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring using a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 175 nm.
- The preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied to caffeine pellets by spraying analogously to example 1.
-
TABLE 5 Composition of pellets: Composition [% by weight] Caffeine 20.0 Lactose 38.5 Microcrystalline 38.5 Kollidon ® CL-F 3.0 100.00 - The constituents were mixed in a Diosna mixer for 3 min and then wetted with water. This wet mass was extruded and then rounded in a rounding machine to give pellets with a diameter of 0.7-1.4 mm.
- Testing the pellets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 87% - 6.7 g of succinic acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized dispersion was spray-dried analogously to example 10 in a FSD spray tower. The average particle size of the powder was 312 μm.
- The spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring using a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 172 nm.
- The preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to theophyllin granules (particle size from 0.2-0.7 mm) analogously to example 1.
- Testing the granules with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 91% - 7.4 g of glutaric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 8 mol %. This partially neutralized dispersion was spray-dried analogously to example 10 in a FSD spray tower. The average particle size of the powder was 295 μm.
- The spray-dried product was redispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering revealed a value of 188 nm.
- The preparation prepared in this way was admixed with 14 g of acetyl triethyl citrate, stirred for two hours and applied by spraying to paracetamol crystals (diameter 0.3 mm) analogously to example 1 by spraying.
- Testing the granules with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 90% - 27.6 g of sodium lauryl sulfate and 14.7 g of fumaric acid were dissolved in 1500 ml of demin. water and then incorporated, with stirring, into 3000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 6 mol %. This partially neutralized spray suspension was spray-dried in a spray tower. The atomization was carried out here via a 1.4 mm two-material nozzle with an atomization pressure of 0.3 MPa. The drying gas was passed tangentially in the input region of the spray dryer and the dried product was separated off in a cyclone. The inlet air temperature was 112° C. and the outlet air temperature 59° C. The average particle size of the powder was 37 μm. 750 g of the spray-dried powder was redispersed in demin. water to give a spray suspension with 20% by weight solids content by stirring for 60 minutes using a propeller stirrer. Measurement of the particle size by means of light scattering showed a monomodal distribution with a maximum at 173 nm. The spray suspension was admixed with 13% by weight of tributyl citrate based on solid polymer and, after stirring for two hours, further processed with the parameters listed in table 5.
-
TABLE 5 Spray conditions: Equipment Manesty Inlet air temperature 60° C. Inlet air amount 450 m3/h Drum speed 14 rpm Batch size 5 kg Core Example 1 Spraying rate 25 g/min Atomization pressure 0.28 MPa Spray width 0.28 MPa Application amount 4 mg/cm2 - Testing the tablets as to resistance in buffer pH 6.8 revealed the following results:
-
30 min 100% 60 min 69% - 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight were spray-dried in a spray tower. Atomization was carried out here via a 1.4 mm two-material nozzle with 0.3 MPa atomization pressure. The drying gas was passed tangentially in the input area of the spray dryer and the dried product was separated off in a cyclone. The inlet air temperature was 109° C. and the outlet air temperature 58° C. The average particle size of the powder was 33 μm.
- 105.1 g of tartaric acid were dissolved in 500 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of the polymer with a solids content of 30% by weight. This corresponds to a degree of neutralization of 100 mol %. This spray suspension was spray-dried in a spray tower analogously to powder A.
- The average particle size of the powder was 35 μm.
- Powder A was mixed with powder B in a Turbula such that a degree of neutralization of 7 mol % was established and then redispersed in demin. water with stirring using paddle stirrers to give a 20% strength by weight dispersion.
- Measurement of the particle size by means of light scattering showed a monomodal distribution with a maximum at 168 nm. After adding 13% by weight of acetyl triethyl citrate based on polymer, the spray suspension was sprayed analogously to example 19 on caffeine cores as per table 1.
- Testing the tables with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results
-
30 min 100% 60 min 72% - 14.2 g of sebacic acid were suspended in 500 ml of demin. water and then incorporated, stirring, into 100 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 100 mol %.
- This solution was incorporated, with stirring, into 1300 ml of an aqueous dispersion of the polymer with a solids content of 30% by weight such that a degree of neutralization of 7 mol % was established. The spray suspension prepared in this way was spray-dried in a FSD spray tower, the atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.3 MPa. The inlet air temperature was 118° C. and the outlet air temperature was 63° C. The fines fraction was separated off during the spray drying and blown again in front of the spray nozzle such that spray-dried particles with an average particle size of 263 μm resulted. 100 g of the spray-dried product was dispersed in water to give a spray suspension with 20% by weight of solids content by stirring with a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering showed a monomodal distribution with a maximum at 178 nm.
- The preparation prepared in this way was admixed with 15% by weight of acetyl triethyl citrate based on solid polymer, stirred for two hours and applied analogously to example 19 by spraying to tablet cores as per table 4.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results:
-
30 min 100% 60 min 78% - 50 g of PEG 6000, 200 g of talc, 9 g of titanium dioxide and 9 g of iron oxide red were mixed in a Turbula mixer and then ground in a pin mill. This mixture was suspended in 250 g of demin. water and applied to 500 g of polymer powder prepared according to example 10 by means of Diosna granulation such that granules with an average particle size of 187 μm result.
-
TABLE 6 Granulation conditions: Equipment Diosna Mixer rotational speed 350 rpm Chopper rotational speed 2000 rpm - 100 g of these granules were dispersed in water to give a spray suspension with 20% by weight solids content by stirring with a paddle stirrer for 60 min. Measuring the particle size by means of light scattering showed a monomodal distribution with a maximum at 177 nm.
- The preparation prepared in this way was admixed with 15% by weight of acetyl triethyl citrate based on solid polymer, stirred for two hours and applied analogously to example 1 by spraying to tablet cores as per table 3.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results:
-
30 min 100% 60 min 82% - 500 g of polymer powder prepared according to example 11 were mixed with 3 g of lecithin, 6 g of stearic acid and 150 g of talc in a Turbula mixer and then further processed by means of a compactor. The flakes produced in this way were ground and then redispersed in demin. water. Measuring the particle size by means of light scattering showed a monomodal distribution with a maximum at 181 nm.
- 2.5% by weight of BHT were dissolved in 15% by weight of acetyl triethyl citrate (based on solid polymer) and then added to the dispersion.
- The preparation prepared in this way was admixed with 15% by weight of acetyl triethyl citrate based on solid polymer, stirred for two hours and applied analogously to example 1 by spraying to tablet cores as per table 1.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results.
-
30 min 100% 60 min 84% - 200 g of talc and 8 g of indigotin lake were suspended in 500 g of demin. water and then applied to 500 g of polymer powder prepared according to example 12 in a fluidized-bed process.
-
TABLE 7 Granulation conditions: Equipment Glatt GPC 1 Inlet air temperature 60° C. Inlet air amount 300 m3/h Batch size 500 g Spraying pressure 0.15 MPa - The average particle size of the granules was ca. 312 μm.
- 100 g of the granules were redispersed in demin. water to give a spray suspension with 20% by weight of solids content by stirring for 60 min with a propeller stirrer. Measurement of the particle size by means of light scattering showed a monomodal distribution with a maximum at 193 nm. The spray suspension was admixed with 13% by weight of tributyl citrate based on solid powder and, after stirring for two hours, further processed analogously to example 19 by spraying onto tablet cores according to table 4.
- For an application amount of 4 mg/cm2, 74% of the coated tablets exhibited a resistance of 100% after 30 min.
- 200 g of talc, 8 g of indigotin lake and 11.9 g of glutaric acid were suspended in 500 g of demin. water and then applied to 500 g of polymer powder prepared according to example 13 in a fluidized-bed process analogously to example 11. This corresponds to a degree of neutralization of 8 mol %.
- The average particle size of the granules was 298 μm.
- 100 g of the granules were redispersed in demin. water to give a spray suspension with 20% by weight solids content by stirring for 60 min using a propellor stirrer. Measurement of the particle size by means of light scattering showed a monomodal distribution with a maximum at 184 nm. The spray suspension was admixed with 13% by weight of tributyl citrates, based on solid polymer, and, after stirring for two hours, was further processed analogously to example 1 by spraying onto tablet cores as per table 3.
- For an application amount of 4 mg/cm2, the coated tablets exhibited a resistance of 83% after 60 min.
- 100 g of talc, 20 g of iron oxide red and 5.2 g of malonic acid were suspended in 300 g of demin. water and then homogenized by means of an Ultra-Turrax for 15 min at 10 000 rpm. This pigment suspension was incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. The spray suspension prepared in this way and having a degree of neutralization of 7 mol % was then spray-dried in a SBD spray tower, atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.30 MPa. The inlet air temperature was 135° C. and the outlet air temperature 63° C. The fines fraction was separated off during the spray-drying and blown again in front of the spray nozzle such that spray-dried particles with an average particle size of 320 μm resulted. The spray-dried product was incorporated in water to give a spray suspension with a solids content of 20% by weight by stirring using a paddle stirrer. The preparation prepared in this way was admixed with 15% triethyl citrate based on solid polymer, stirred for a further two hours and applied by spraying to tablet cores (table 1) analogously to example 1.
- The coated tablets with an application amount of 4 mg/cm2 exhibited a resistance of 100% after 60 min in buffer pH 6.8.
- 100 g of polymer powder prepared according to example 10 were mixed with 50 g of talc and 4 g of indigotin lake in a Turbula mixer.
- Redispersing this preparation in water to give a 20% strength by weight suspension using a paddle stirrer produced a particle size of 182 nm. The suspension was admixed with 15% by weight of dibutyl sebacate and, after stirring for two hours, sprayed onto tablets according to table 4 analogously to example 1. For an application amount of 4 mg/cm2, the coated tablets exhibited a resistance of 100% after 30 min and a resistance of 78% after 60 min.
- 100 g of polymer powder prepared according to example 13 were mixed with 50 g of very finely ground talc, 4 g of indigotin lake and 2.3 g of sebacic acid in a Turbula mixer.
- After redispersing this preparation in water to give a 20% strength by weight suspension with a degree of neutralization of 5 mol % by means of a paddle stirrer, the particle size was 175 nm. The suspension was admixed with 15% by weight of dibutyl sebacate and 0.5% Simethicon® and, after stirring for two hours, sprayed analogously to example 1 onto tablets according to table 4. For an application amount of 4 mg/cm2, the coated tablets exhibited a resistance of 100% after 30 min.
- 100 g of polymer powder prepared according to example 11 were mixed with 60 g of talc, 6 g of iron oxide red and 0.5 g of lecithin in a Turbula mixer and then ground in a pin mill. Redispersion of this preparation in water to give a 20% strength by weight suspension by means of a paddle stirrer produced a particle size of 176 nm, talc and ion oxide having been centrifuged off beforehand for this determination.
- The suspension was admixed with 15% by weight of dibutyl sebacate and, after stirring for two hours, sprayed analogously to example 19 onto tablets according to table 1. For an application amount of 4 mg/cm2, the coated tablets exhibited a resistance of 83% after 60 min.
- 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight were spray-dried in an SBD spray tower, the atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.3 MPa. The inlet air temperature was 110° C. and the outlet air temperature 57° C. The fines fraction was separated off during the spray-drying and blown again in front of the spray nozzle such that spray-dried particles with an average particle size of 190 μm resulted.
- 30 g of titanium dioxide, 200 g of talc, 8.4 g of adipic acid and 25 g of iron oxide were ground in a pin mill, then mixed with the spray-dried powder and redispersed in demin. water to give a spray suspension with 20% by weight solids content by stirring using a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering produced a value of 170 nm. The preparation prepared in this way was admixed with 15% by weight of triethyl citrate, based on solid polymer, stirred for two hours and applied analogously to example 19 by spraying onto tablet cores according to table 1.
- Testing the tablets as to resistance in buffer pH 6.8 revealed the following results:
-
30 min 100% 60 min 76% - 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight were spray-dried in a spray tower, the atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.3 MPa. The inlet air temperature was 112° C. and the outlet air temperature 58° C.
- This powder was mixed with 8.4 g of finely powdered adipic acid, 60 g of fine talc, 2 g of fine xanthan, 15 g of fine iron oxide red and then redispersed with stirring in water to give a spray suspension with 20% solids content by stirring using a paddle stirrer for 60 min. Measurement of the particle size by means of light scattering produced a value of 168 nm, talc and iron oxide having been centrifuged off beforehand for this determination.
- The preparation prepared in this way was admixed with 15% by weight of triethyl citrate, based on solid polymer, stirred for two hours and applied analogously to example 19 by spraying onto tablet cores according to table 1.
- Testing the tablets as to resistance in buffer pH 6.8 revealed the following results.
-
30 min 100% 60 min 79% - 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight were spray-dried in an FSD spray tower, the atomization taking place via a 1.4 mm two-material nozzle at an atomization pressure of 0.3 MPa. The inlet air temperature was 123° C. and the outlet air temperature 54° C. The fines fraction was separated off during the spray-drying and blown again in front of the spray nozzle such that spray-dried particles with an average particle size of 211 μm resulted.
- 15.1 g/37.7 g/75.5 g of malic acid were dissolved in each case in 1000 ml of demin. water and then 250 g of the spray-dried powder were incorporated, with stirring, into the respective malic acid solution using a paddle stirrer. This corresponds to a degree of neutralization of 2, 5 or 10 mol %. After a redispersion time of 60 min, the average particle size of the respective dispersions was 220/198/182 nm.
- The preparation prepared in this way was admixed with 35 g of acetyl triethyl citrate, stirred for two hours and applied analogously to example 1 by spraying onto tablet cores according to table 3.
- Testing the tablets with an application amount of 4 mg/cm2 as to resistance in buffer pH 6.8 revealed the following results.
-
2 mol % 5 mol % 10 mol % 30 min 100% 100% 100% 60 min 37% 65% 89% - 1.3 g of succinic acid, 1.2 g of fumaric acid and 1.6 g of tartaric acid were each dissolved in 150 ml of demin. water and then incorporated, with stirring, into 1000 ml of an aqueous dispersion of polymer A with a solids content of 30% by weight. This corresponds to a degree of neutralization of 1.5 mol % in each case. This partially neutralized spray suspension was spray-dried analogously to example 1 in a spray tower.
- The average particle size of the powder was 37 μm.
- The powder was redispersed analogously to example 1 and shows a monomodal distribution with a maximum at 182 nm.
- Further processing to give film tablets with an application amount of 4 mg/cm2 was carried out analogously to example 1.
- Testing the tablets as to resistance in buffer pH 6.8 revealed the following results:
-
30 min 100% 60 min 72%
Claims (25)
1. A pharmaceutical coating obtained from a film-forming coating composition based on a copolymer of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, where the copolymer is partially neutralized with a C3-C10-dicarboxylic acid.
2. The coating of claim 1 , wherein the copolymer is partially neutralized with an unbranched C3-C10-dicarboxylic acid.
3. The coating of claim 1 , wherein the dicarboxylic acid comprises fumaric acid.
4. The coating of claim 1 , wherein the dicarboxylic acid comprises an alkanedicarboxylic acid.
5. The coating of claim 1 , wherein the dicarboxylic acid is selected from the group consisting of malonic acid, succinic acid, glutaric acid, adipic acid or sebacic acid, malic acid (2-hydroxysuccinic acid) and tartaric acid (2,3-dihydroxysuccinic acid).
6. The coating of claim 1 , wherein the copolymer is partially neutralized to 2 to 15 mol %.
7. The coating of claim 6 , wherein the copolymer is partially neutralized to 4 to 10 mol %.
8. The coating of claim 1 , the dicarboxylic acid comprising dicarboxylic acids which have a first pKa value of greater than 2 and a second pKa value of greater than 4.
9. The coating of claim 5 , the dicarboxylic acid comprising adipic acid.
10. A dosage form comprising a pharmaceutical active ingredient and the coating composition according to claim 1 .
11. The dosage form of claim 10 , wherein the coating composition is applied in an amount in the range of 1 to 20 mg/cm2
12. The dosage form of claim 10 , wherein upon application of the coating composition in an amount of 4 mg/cm2, having a resistance to release of the pharmaceutical active ingredient in an aqueous environment at pH 6.8 of at least 80% after 30 min.
13. The dosage form of claim 10 , wherein the coating composition is obtained by applying an aqueous coating which is prepared by redispersing the coating composition from a powder form.
14. A method for producing a film-forming coating composition for a dosage form comprising at least one pharmaceutical active ingredient and having a resistance to premature release of the active ingredient, the method comprising
forming the coating composition comprising a copolymer of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, and
partially neutralizing the copolymers in the coating composition with a C3-C10-dicarboxylic acid.
15. The method of claim 14 , wherein the partially neutralizing step occurs with the dicarboxylic acid in an aqueous dispersion.
16. The method of claim 14 , wherein the copolymer is partially neutralized in powder form.
17. The method of claim 14 , wherein the copolymer is partially neutralized to 2 to 15 mol %.
18. The method of claim 17 , wherein the copolymer is partially neutralized to 4 to 10 mol %.
19. The method of claim 18 , wherein the copolymer is partially neutralized with an unbranched C3-C10-dicarboxylic acid.
20. The method of claim 14 , wherein the dicarboxylic acid comprises an alkane dicarboxylic acid.
21. The method of claim 20 , wherein the dicarboxylic acid is selected from the group consisting of malonic acid, succinic acid, glutaric acid, adipic acid or sebacic acid, malic acid (2-hydroxysuccinic acid) and tartaric acid (2,3-dihydroxysuccinic acid).
22. The method of claim 21 , wherein the dicarboxylic acid comprises adipic acid.
23. The method of claim 14 , wherein the dicarboxylic acid comprises fumaric acid.
24. The method of claim 14 further comprising redispersing the coating composition in water prior to application to a dosage form.
25. A method of making a dosage form comprising using the coating composition of claim 1 and applying it to an active ingredient, the coating composition providing protection against premature release of the active ingredient in an aqueous environment at pH 6.8.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/790,101 US20130236505A1 (en) | 2012-03-09 | 2013-03-08 | Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment |
| US15/848,124 US10912835B2 (en) | 2012-03-09 | 2017-12-20 | Production of pharmaceutical protective coatings with good resistance in a neutral environment |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608655P | 2012-03-09 | 2012-03-09 | |
| US13/790,101 US20130236505A1 (en) | 2012-03-09 | 2013-03-08 | Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/848,124 Division US10912835B2 (en) | 2012-03-09 | 2017-12-20 | Production of pharmaceutical protective coatings with good resistance in a neutral environment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20130236505A1 true US20130236505A1 (en) | 2013-09-12 |
Family
ID=49114320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/790,101 Abandoned US20130236505A1 (en) | 2012-03-09 | 2013-03-08 | Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment |
| US15/848,124 Active US10912835B2 (en) | 2012-03-09 | 2017-12-20 | Production of pharmaceutical protective coatings with good resistance in a neutral environment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/848,124 Active US10912835B2 (en) | 2012-03-09 | 2017-12-20 | Production of pharmaceutical protective coatings with good resistance in a neutral environment |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20130236505A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140086992A1 (en) * | 2012-09-27 | 2014-03-27 | Basf Se | Storage-Stable Dust-Free Homogeneous Particulate Formulation |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| US11344562B2 (en) | 2017-08-15 | 2022-05-31 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220553A1 (en) * | 2005-06-16 | 2009-09-03 | Mohammed Saeed | Composition and Method for Inhibiting, Preventing, or Ameliorating Complications Associated With Ingestion of a Medicinal, Chemical, or Biological Substance or Agent |
| WO2012089778A1 (en) * | 2010-12-28 | 2012-07-05 | Hexal Ag | Pharmaceutical formulation comprising a biopharmaceutical drug |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1219175B (en) | 1965-02-24 | 1966-06-16 | Bayer Ag | Process for the production of active ingredient preparations protected against the action of rumen juices from ruminants |
| DE2135073C3 (en) | 1971-07-14 | 1974-07-11 | Roehm Gmbh | Coating agents for dosage forms |
| DE2512238C2 (en) | 1975-03-20 | 1977-01-13 | Roehm Gmbh | BINDERS FOR DRUG COATINGS |
| DE3049179A1 (en) | 1975-03-20 | 1982-07-29 | Röhm GmbH, 6100 Darmstadt | Using vinyl! copolymer as binding agent for pharmaceutical dosages - prepd. by dispersing the copolymer spray-dried powder in softening soln. |
| DE3208791A1 (en) | 1982-03-11 | 1983-09-22 | Röhm GmbH, 6100 Darmstadt | METHOD FOR COATING MEDICINAL PRODUCTS BY MEANS OF A COATING AGENT DISPERSED IN WATER |
| ES2032281T3 (en) | 1986-08-07 | 1993-02-01 | Rohm Gmbh | PROCEDURE FOR THE PREPARATION OF A REDISPERSIBLE PLASTIC MATERIAL POWDER. |
| DE19617716A1 (en) | 1996-05-03 | 1997-11-06 | Basf Ag | Polymer powder redispersible in aqueous solution |
| DE19918435A1 (en) | 1998-07-23 | 2000-01-27 | Roehm Gmbh | Coating or binding agent for medicaments, prepared using finely divided acrylic copolymer powder, used e.g. for taste-masking coatings or in transdermal delivery systems |
| CN1192767C (en) | 2001-02-27 | 2005-03-16 | 罗姆两合公司 | Coatings and binders for pharmaceutical preparations with improved storage stability |
| DE10239999A1 (en) | 2002-08-27 | 2004-03-04 | Röhm GmbH & Co. KG | Granules or powders for the preparation of coating and binding agents for dosage forms |
| CN101283008A (en) | 2005-08-11 | 2008-10-08 | 巴斯夫欧洲公司 | Copolymers based on N-vinylcaprolactam and their use as solubilizers |
| DE102005053066A1 (en) | 2005-11-04 | 2007-05-10 | Basf Ag | Use of copolymers as solubilizers for sparingly water-soluble compounds |
| EP1962908A2 (en) | 2005-12-09 | 2008-09-03 | Basf Se | Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilisers for poorly water-soluble compounds |
| WO2007065845A1 (en) | 2005-12-09 | 2007-06-14 | Basf Se | Copolymers based on polyalkylene oxide-modified n-vinyl lactam copolymers |
| US8790693B2 (en) | 2007-08-02 | 2014-07-29 | Basf Se | Aqueous polymer dispersion based on N,N-diethylaminoethyl methacrylate, its preparation and use |
| EP2437734A2 (en) | 2009-06-04 | 2012-04-11 | Basf Se | Orally disintegrating dosage forms containing taste-masked active ingredients |
| US20120059054A1 (en) | 2010-09-07 | 2012-03-08 | Basf Se | Use Of Copolymers Based On Amino-Containing Polymers As Matrix Binders In Preparing Active Compound-Containing Granules And Administration Forms |
| WO2012031934A1 (en) | 2010-09-07 | 2012-03-15 | Basf Se | Use of copolymers based on polymers containing amino groups as a matrix binder for the production of active ingredient-containing granules and administration forms |
| JP6012604B2 (en) | 2010-09-27 | 2016-10-25 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Protective coating for acidic active ingredients |
| BR112013020877B1 (en) | 2011-02-28 | 2020-06-02 | Basf Se | PROCESS TO PRODUCE PULVERULENT COATING COMPOSITIONS |
| WO2012116941A1 (en) | 2011-02-28 | 2012-09-07 | Basf Se | Producing powdery coating agents for stable protective coatings for pharmaceutical dosage forms |
| WO2013045352A1 (en) | 2011-09-30 | 2013-04-04 | Basf Se | Method for producing solid pigment-containing film coating agents in the form of granular materials on the basis of film formers that are resistant to gastric juice for pharmaceutical dosage forms |
| EP2636403A1 (en) | 2012-03-09 | 2013-09-11 | Basf Se | Production of pharmaceutical protective overalls with good resistance in a neutral environment |
-
2013
- 2013-03-08 US US13/790,101 patent/US20130236505A1/en not_active Abandoned
-
2017
- 2017-12-20 US US15/848,124 patent/US10912835B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220553A1 (en) * | 2005-06-16 | 2009-09-03 | Mohammed Saeed | Composition and Method for Inhibiting, Preventing, or Ameliorating Complications Associated With Ingestion of a Medicinal, Chemical, or Biological Substance or Agent |
| WO2012089778A1 (en) * | 2010-12-28 | 2012-07-05 | Hexal Ag | Pharmaceutical formulation comprising a biopharmaceutical drug |
Non-Patent Citations (1)
| Title |
|---|
| Kollicoat� Smartseal 30 D, BASF, October 2010. * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| US20140086992A1 (en) * | 2012-09-27 | 2014-03-27 | Basf Se | Storage-Stable Dust-Free Homogeneous Particulate Formulation |
| US9789063B2 (en) * | 2012-09-27 | 2017-10-17 | Basf Se | Storage-stable dust-free homogeneous particulate formulation |
| US11344562B2 (en) | 2017-08-15 | 2022-05-31 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| US12303520B2 (en) | 2017-08-15 | 2025-05-20 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180110858A1 (en) | 2018-04-26 |
| US10912835B2 (en) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120076858A1 (en) | Orally Disintegrating Dosage Forms Containing Taste-Masked Active Ingredients | |
| US7175857B2 (en) | Granulate or powder for producing coating or binding agents for medicaments | |
| EP1556016B1 (en) | Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers | |
| EP2613770A1 (en) | Use of copolymers based on polymers containing amino groups as a matrix binder for the production of active ingredient-containing granules and administration forms | |
| MXPA05006284A (en) | Methods for coating substrates for pharmaceutical uses with a mixture of two film-forming coating agents. | |
| US10912835B2 (en) | Production of pharmaceutical protective coatings with good resistance in a neutral environment | |
| JP6130013B2 (en) | Production of powder coatings for stable protective coatings for pharmaceutical dosage forms | |
| JP6027550B2 (en) | Production of powder coatings for stable protective coatings for pharmaceutical dosage forms | |
| US8962064B2 (en) | Production of pulverulent coating compositions for stable protective coatings for pharmaceutical dosage forms | |
| CN104159576B (en) | The preparation of the medicament protection coating with good resistance in neutral environment | |
| US8865250B2 (en) | Production of pulverulent coating compositions for stable protective coatings for pharmaceutical dosage forms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: BASF SE, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOLTER, KARL;GEBERT, SILKE;MUELLER, MICHAEL KLEMENS;AND OTHERS;SIGNING DATES FROM 20121128 TO 20121205;REEL/FRAME:029951/0802 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |